US20090258834A1 - Plasma protein-binding ligands - Google Patents
Plasma protein-binding ligands Download PDFInfo
- Publication number
- US20090258834A1 US20090258834A1 US11/802,730 US80273007A US2009258834A1 US 20090258834 A1 US20090258834 A1 US 20090258834A1 US 80273007 A US80273007 A US 80273007A US 2009258834 A1 US2009258834 A1 US 2009258834A1
- Authority
- US
- United States
- Prior art keywords
- peptide
- xaa
- amino acid
- seq
- isolated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000004506 Blood Proteins Human genes 0.000 title abstract description 57
- 108010017384 Blood Proteins Proteins 0.000 title abstract description 57
- 239000003446 ligand Substances 0.000 title description 104
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 235
- 150000001413 amino acids Chemical class 0.000 claims abstract description 183
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 76
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 76
- 229940012952 fibrinogen Drugs 0.000 claims abstract description 67
- 108010049003 Fibrinogen Proteins 0.000 claims abstract description 66
- 102000008946 Fibrinogen Human genes 0.000 claims abstract description 66
- 108010047303 von Willebrand Factor Proteins 0.000 claims abstract description 61
- 102100036537 von Willebrand factor Human genes 0.000 claims abstract description 61
- 229960001134 von willebrand factor Drugs 0.000 claims abstract description 61
- 102000006996 Aryldialkylphosphatase Human genes 0.000 claims abstract description 55
- 108010008184 Aryldialkylphosphatase Proteins 0.000 claims abstract description 55
- 102000005666 Apolipoprotein A-I Human genes 0.000 claims abstract description 42
- 108010059886 Apolipoprotein A-I Proteins 0.000 claims abstract description 42
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 claims abstract description 4
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 81
- 239000000203 mixture Substances 0.000 claims description 31
- 229960000301 factor viii Drugs 0.000 claims description 30
- 239000012528 membrane Substances 0.000 claims description 30
- 108010054218 Factor VIII Proteins 0.000 claims description 29
- 102000001690 Factor VIII Human genes 0.000 claims description 29
- 230000002209 hydrophobic effect Effects 0.000 claims description 29
- -1 aromatic amino acid Chemical class 0.000 claims description 26
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 11
- 239000012539 chromatography resin Substances 0.000 claims description 11
- 230000002378 acidificating effect Effects 0.000 claims description 10
- 150000008574 D-amino acids Chemical group 0.000 claims description 8
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims description 7
- 150000001408 amides Chemical class 0.000 claims description 6
- IYKLZBIWFXPUCS-VIFPVBQESA-N (2s)-2-(naphthalen-1-ylamino)propanoic acid Chemical compound C1=CC=C2C(N[C@@H](C)C(O)=O)=CC=CC2=C1 IYKLZBIWFXPUCS-VIFPVBQESA-N 0.000 claims description 4
- RWLSBXBFZHDHHX-VIFPVBQESA-N (2s)-2-(naphthalen-2-ylamino)propanoic acid Chemical compound C1=CC=CC2=CC(N[C@@H](C)C(O)=O)=CC=C21 RWLSBXBFZHDHHX-VIFPVBQESA-N 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 150000008575 L-amino acids Chemical class 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 12
- 229940024606 amino acid Drugs 0.000 description 99
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 88
- 229920005989 resin Polymers 0.000 description 67
- 239000011347 resin Substances 0.000 description 67
- 210000002381 plasma Anatomy 0.000 description 60
- 235000018102 proteins Nutrition 0.000 description 54
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 48
- 239000012508 resin bead Substances 0.000 description 46
- 239000011780 sodium chloride Substances 0.000 description 44
- 239000000872 buffer Substances 0.000 description 42
- 239000011324 bead Substances 0.000 description 29
- 239000001509 sodium citrate Substances 0.000 description 21
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 21
- 102000009027 Albumins Human genes 0.000 description 20
- 108010088751 Albumins Proteins 0.000 description 20
- 230000000694 effects Effects 0.000 description 20
- 238000000746 purification Methods 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 18
- 229920000936 Agarose Polymers 0.000 description 15
- 102000015779 HDL Lipoproteins Human genes 0.000 description 15
- 108010010234 HDL Lipoproteins Proteins 0.000 description 15
- 238000001514 detection method Methods 0.000 description 15
- 238000010828 elution Methods 0.000 description 15
- 229960004198 guanidine Drugs 0.000 description 15
- 238000011084 recovery Methods 0.000 description 15
- 239000000499 gel Substances 0.000 description 14
- 102000004196 processed proteins & peptides Human genes 0.000 description 14
- 239000000523 sample Substances 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 239000002245 particle Substances 0.000 description 12
- 208000027418 Wounds and injury Diseases 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 239000000758 substrate Substances 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 239000011159 matrix material Substances 0.000 description 10
- 238000005406 washing Methods 0.000 description 10
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 9
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 9
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- 229920001213 Polysorbate 20 Polymers 0.000 description 8
- 206010052428 Wound Diseases 0.000 description 8
- 238000001042 affinity chromatography Methods 0.000 description 8
- 239000011543 agarose gel Substances 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 8
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 8
- 108010007622 LDL Lipoproteins Proteins 0.000 description 7
- 102000007330 LDL Lipoproteins Human genes 0.000 description 7
- 230000035602 clotting Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- 241000283707 Capra Species 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- 239000002033 PVDF binder Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 108700004121 sarkosyl Proteins 0.000 description 6
- 229940016590 sarkosyl Drugs 0.000 description 6
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- VWJLJHZPMZGDDV-HOCDWTQPSA-N (4s)-4-amino-5-[[(2s)-1-[[(2s,3s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](N)CCC(O)=O)C1=CN=CN1 VWJLJHZPMZGDDV-HOCDWTQPSA-N 0.000 description 5
- 102100026735 Coagulation factor VIII Human genes 0.000 description 5
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000004087 circulation Effects 0.000 description 5
- 238000000502 dialysis Methods 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 208000031169 hemorrhagic disease Diseases 0.000 description 5
- 239000007943 implant Substances 0.000 description 5
- 229920000136 polysorbate Polymers 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 102000009123 Fibrin Human genes 0.000 description 4
- 108010073385 Fibrin Proteins 0.000 description 4
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 4
- 208000009292 Hemophilia A Diseases 0.000 description 4
- 241001494479 Pecora Species 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 229960002684 aminocaproic acid Drugs 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 229950003499 fibrin Drugs 0.000 description 4
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 201000003542 Factor VIII deficiency Diseases 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 102000008100 Human Serum Albumin Human genes 0.000 description 3
- 108091006905 Human Serum Albumin Proteins 0.000 description 3
- 208000027276 Von Willebrand disease Diseases 0.000 description 3
- QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 3
- 239000012131 assay buffer Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 238000007820 coagulation assay Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 3
- 230000023597 hemostasis Effects 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 108010071584 oxidized low density lipoprotein Proteins 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000000451 tissue damage Effects 0.000 description 3
- 231100000827 tissue damage Toxicity 0.000 description 3
- 208000012137 von Willebrand disease (hereditary or acquired) Diseases 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- QWXZOFZKSQXPDC-NSHDSACASA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](C)C(O)=O)C3=CC=CC=C3C2=C1 QWXZOFZKSQXPDC-NSHDSACASA-N 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 2
- OYIFNHCXNCRBQI-UHFFFAOYSA-N 2-aminoadipic acid Chemical compound OC(=O)C(N)CCCC(O)=O OYIFNHCXNCRBQI-UHFFFAOYSA-N 0.000 description 2
- RDFMDVXONNIGBC-UHFFFAOYSA-N 2-aminoheptanoic acid Chemical compound CCCCCC(N)C(O)=O RDFMDVXONNIGBC-UHFFFAOYSA-N 0.000 description 2
- SNDPXSYFESPGGJ-UHFFFAOYSA-N 2-aminopentanoic acid Chemical compound CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 2
- PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical compound [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 description 2
- YSMODUONRAFBET-UHFFFAOYSA-N 5-hydroxylysine Chemical group NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 206010009192 Circulatory collapse Diseases 0.000 description 2
- 206010053567 Coagulopathies Diseases 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 241000393496 Electra Species 0.000 description 2
- 206010014824 Endotoxic shock Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- JUQLUIFNNFIIKC-YFKPBYRVSA-N L-2-aminopimelic acid Chemical compound OC(=O)[C@@H](N)CCCCC(O)=O JUQLUIFNNFIIKC-YFKPBYRVSA-N 0.000 description 2
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
- 108010028275 Leukocyte Elastase Proteins 0.000 description 2
- 102000016799 Leukocyte elastase Human genes 0.000 description 2
- AKCRVYNORCOYQT-YFKPBYRVSA-N N-methyl-L-valine Chemical compound CN[C@@H](C(C)C)C(O)=O AKCRVYNORCOYQT-YFKPBYRVSA-N 0.000 description 2
- KSPIYJQBLVDRRI-UHFFFAOYSA-N N-methylisoleucine Chemical compound CCC(C)C(NC)C(O)=O KSPIYJQBLVDRRI-UHFFFAOYSA-N 0.000 description 2
- 229920002274 Nalgene Polymers 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 108010067372 Pancreatic elastase Proteins 0.000 description 2
- 102000016387 Pancreatic elastase Human genes 0.000 description 2
- 108010067902 Peptide Library Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 208000004210 Pressure Ulcer Diseases 0.000 description 2
- 108010077895 Sarcosine Proteins 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000006180 TBST buffer Substances 0.000 description 2
- MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 description 2
- 229920003180 amino resin Polymers 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 102000028848 arylesterase Human genes 0.000 description 2
- 108010009043 arylesterase Proteins 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- VEVRNHHLCPGNDU-MUGJNUQGSA-O desmosine Chemical compound OC(=O)[C@@H](N)CCCC[N+]1=CC(CC[C@H](N)C(O)=O)=C(CCC[C@H](N)C(O)=O)C(CC[C@H](N)C(O)=O)=C1 VEVRNHHLCPGNDU-MUGJNUQGSA-O 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000011067 equilibration Methods 0.000 description 2
- 235000013861 fat-free Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 229940106780 human fibrinogen Drugs 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 150000002484 inorganic compounds Chemical class 0.000 description 2
- 229910010272 inorganic material Inorganic materials 0.000 description 2
- RGXCTRIQQODGIZ-UHFFFAOYSA-O isodesmosine Chemical compound OC(=O)C(N)CCCC[N+]1=CC(CCC(N)C(O)=O)=CC(CCC(N)C(O)=O)=C1CCCC(N)C(O)=O RGXCTRIQQODGIZ-UHFFFAOYSA-O 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- CMWYAOXYQATXSI-UHFFFAOYSA-N n,n-dimethylformamide;piperidine Chemical compound CN(C)C=O.C1CCNCC1 CMWYAOXYQATXSI-UHFFFAOYSA-N 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000007505 plaque formation Effects 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 230000004141 reverse cholesterol transport Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- BJBUEDPLEOHJGE-UHFFFAOYSA-N (2R,3S)-3-Hydroxy-2-pyrolidinecarboxylic acid Natural products OC1CCNC1C(O)=O BJBUEDPLEOHJGE-UHFFFAOYSA-N 0.000 description 1
- QVHJQCGUWFKTSE-YFKPBYRVSA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)OC(C)(C)C QVHJQCGUWFKTSE-YFKPBYRVSA-N 0.000 description 1
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 1
- XABCFXXGZPWJQP-BYPYZUCNSA-N (S)-3-aminoadipic acid Chemical compound OC(=O)C[C@@H](N)CCC(O)=O XABCFXXGZPWJQP-BYPYZUCNSA-N 0.000 description 1
- CHRJZRDFSQHIFI-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;styrene Chemical compound C=CC1=CC=CC=C1.C=CC1=CC=CC=C1C=C CHRJZRDFSQHIFI-UHFFFAOYSA-N 0.000 description 1
- JHTPBGFVWWSHDL-UHFFFAOYSA-N 1,4-dichloro-2-isothiocyanatobenzene Chemical compound ClC1=CC=C(Cl)C(N=C=S)=C1 JHTPBGFVWWSHDL-UHFFFAOYSA-N 0.000 description 1
- XDPFSAXBVHBYLO-UHFFFAOYSA-N 1h-diazonine Chemical compound C=1C=CC=NNC=CC=1 XDPFSAXBVHBYLO-UHFFFAOYSA-N 0.000 description 1
- OGNSCSPNOLGXSM-UHFFFAOYSA-N 2,4-diaminobutyric acid Chemical compound NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- GMKMEZVLHJARHF-UHFFFAOYSA-N 2,6-diaminopimelic acid Chemical compound OC(=O)C(N)CCCC(N)C(O)=O GMKMEZVLHJARHF-UHFFFAOYSA-N 0.000 description 1
- XABCFXXGZPWJQP-UHFFFAOYSA-N 3-aminoadipic acid Chemical compound OC(=O)CC(N)CCC(O)=O XABCFXXGZPWJQP-UHFFFAOYSA-N 0.000 description 1
- QCHPKSFMDHPSNR-UHFFFAOYSA-N 3-aminoisobutyric acid Chemical compound NCC(C)C(O)=O QCHPKSFMDHPSNR-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 102000012440 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 108010092674 Enkephalins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100025306 Integrin alpha-IIb Human genes 0.000 description 1
- 101710149643 Integrin alpha-IIb Proteins 0.000 description 1
- 208000032984 Intraoperative Complications Diseases 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- AGPKZVBTJJNPAG-UHNVWZDZSA-N L-allo-Isoleucine Chemical compound CC[C@@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-UHNVWZDZSA-N 0.000 description 1
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- PQNASZJZHFPQLE-LURJTMIESA-N N(6)-methyl-L-lysine Chemical compound CNCCCC[C@H](N)C(O)=O PQNASZJZHFPQLE-LURJTMIESA-N 0.000 description 1
- OLNLSTNFRUFTLM-BYPYZUCNSA-N N-ethyl-L-asparagine Chemical compound CCN[C@H](C(O)=O)CC(N)=O OLNLSTNFRUFTLM-BYPYZUCNSA-N 0.000 description 1
- OLNLSTNFRUFTLM-UHFFFAOYSA-N N-ethylasparagine Chemical compound CCNC(C(O)=O)CC(N)=O OLNLSTNFRUFTLM-UHFFFAOYSA-N 0.000 description 1
- YPIGGYHFMKJNKV-UHFFFAOYSA-N N-ethylglycine Chemical compound CC[NH2+]CC([O-])=O YPIGGYHFMKJNKV-UHFFFAOYSA-N 0.000 description 1
- 108010065338 N-ethylglycine Proteins 0.000 description 1
- KSPIYJQBLVDRRI-WDSKDSINSA-N N-methyl-L-isoleucine Chemical compound CC[C@H](C)[C@H](NC)C(O)=O KSPIYJQBLVDRRI-WDSKDSINSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 208000007964 Organophosphate Poisoning Diseases 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 229920002319 Poly(methyl acrylate) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- DYAHQFWOVKZOOW-UHFFFAOYSA-N Sarin Chemical compound CC(C)OP(C)(F)=O DYAHQFWOVKZOOW-UHFFFAOYSA-N 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 101710187074 Serine proteinase inhibitor Proteins 0.000 description 1
- 244000191761 Sida cordifolia Species 0.000 description 1
- GRXKLBBBQUKJJZ-UHFFFAOYSA-N Soman Chemical compound CC(C)(C)C(C)OP(C)(F)=O GRXKLBBBQUKJJZ-UHFFFAOYSA-N 0.000 description 1
- 229920001872 Spider silk Polymers 0.000 description 1
- 101100046503 Symbiobacterium thermophilum (strain T / IAM 14863) tnaA1 gene Proteins 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000212749 Zesius chrysomallus Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000004645 aluminates Chemical class 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- WLDHEUZGFKACJH-UHFFFAOYSA-K amaranth Chemical compound [Na+].[Na+].[Na+].C12=CC=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(O)=C1N=NC1=CC=C(S([O-])(=O)=O)C2=CC=CC=C12 WLDHEUZGFKACJH-UHFFFAOYSA-K 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 239000005312 bioglass Substances 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000008045 co-localization Effects 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000010217 densitometric analysis Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000006167 equilibration buffer Substances 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 238000011194 good manufacturing practice Methods 0.000 description 1
- 239000011544 gradient gel Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000032630 lymph circulation Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 238000004848 nephelometry Methods 0.000 description 1
- 239000003958 nerve gas Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- WYMSBXTXOHUIGT-UHFFFAOYSA-N paraoxon Chemical compound CCOP(=O)(OCC)OC1=CC=C([N+]([O-])=O)C=C1 WYMSBXTXOHUIGT-UHFFFAOYSA-N 0.000 description 1
- 229960004623 paraoxon Drugs 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 229950011087 perflunafene Drugs 0.000 description 1
- UWEYRJFJVCLAGH-IJWZVTFUSA-N perfluorodecalin Chemical compound FC1(F)C(F)(F)C(F)(F)C(F)(F)[C@@]2(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)[C@@]21F UWEYRJFJVCLAGH-IJWZVTFUSA-N 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000003805 procoagulant Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229940099982 prolastin Drugs 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000000565 sealant Substances 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- 239000003001 serine protease inhibitor Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000010414 supernatant solution Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 description 1
- YSMODUONRAFBET-WHFBIAKZSA-N threo-5-hydroxy-L-lysine Chemical compound NC[C@@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-WHFBIAKZSA-N 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 239000002407 tissue scaffold Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- BJBUEDPLEOHJGE-IMJSIDKUSA-N trans-3-hydroxy-L-proline Chemical compound O[C@H]1CC[NH2+][C@@H]1C([O-])=O BJBUEDPLEOHJGE-IMJSIDKUSA-N 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
- C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0815—Tripeptides with the first amino acid being basic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54386—Analytical elements
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Definitions
- Peptide ligands consist of only a few amino acids, which, unlike large murine antibodies, are not likely to cause an immune response if contamination of the purification product occurs. Peptide ligands also are more stable compared to antibodies, and can be manufactured aseptically in large quantities under Good Manufacturing Practice conditions. The interactions between peptide ligands and target proteins can be easily modified to allow mild elution conditions for separation and to provide greater control of interactions by the practitioner.
- the invention provides an isolated or purified peptide (i.e., ligand) that binds to a plasma protein.
- the invention provides an isolated or purified peptide that binds to fibrinogen, a complex comprising Apo-A1 lipoprotein and paraoxonase, al proteinase inhibitor (API), and/or von Willebrand Factor (vWF).
- the isolated or purified peptide ligand is useful in a variety of contexts, including separation of plasma proteins from complex mixtures or samples, binding (e.g., immobilization) of plasma proteins to porous or non-porous surfaces, probes, sequestration of plasma proteins, coatings for medical and research devices, and therapeutics.
- Fibrinogen is the precursor of fibrin, the major protein involved in the clotting of blood. Fibrinogen is comprised of three pairs of polypeptides (A ⁇ , B ⁇ , and ⁇ ) joined by disulfide bonds, which, upon cleavage of the A ⁇ - and B ⁇ -chains by thrombin, convert fibrinogen into fibrin.
- the fibrinogen-binding peptide comprises or consists essentially of no more than 10 amino acids and comprises an amino acid sequence Xaa 1 -Xaa 2 -Xaa 3 -Xaa 4 -Xaa 5 (SEQ ID NO: 1).
- the invention provides an isolated or purified fibrinogen-binding peptide comprising an amino acid sequence Gly-Xaa 6 -Arg-Xaa 7 (SEQ ID NO: 2), wherein Xaa 6 is Pro or Gln (preferably Pro), and Xaa 7 is any amino acid except Pro.
- the peptide comprises or consists essentially of no more than 10 amino acids.
- the amino acid sequence comprises a D-amino acid at the N-terminus.
- the isolated or purified peptide of the invention comprises or consists essentially of no more than 10 amino acids.
- a peptide ligand can comprise amino acids in addition to the amino acid sequence specifically set forth herein and designated a SEQ ID NO.
- the fibrinogen-binding peptide of the invention can consist essentially of 10 amino acids, six of which are ARQFDF (SEQ ID NO: 20), a plasma protein (e.g., fibrinogen)-binding motif.
- the remaining one, two, three, or four amino acids can be on the N- or, preferably, the C-terminus of the plasma protein-binding motif and should not prevent contact of the plasma protein-binding motif with the target plasma protein.
- the isolated or purified peptide of the invention binds to one or more plasma proteins, namely fibrinogen, API, a complex comprising Apo-A1 lipoprotein and paraoxonase, and/or vWF.
- the isolated or purified peptide comprises or consists essentially of an amino acid sequence that binds to a plasma protein (in, for example, a mixed sample) with moderate to strong avidity under controlled conditions of pH, ionic strength, and solvent composition.
- the binding avidity can be modulated by the presence of amino acids adjacent to the plasma protein-binding motif.
- binding avidity can be decreased or increased by substituting single amino acids and/or by terminal deletion of amino acids in the amino acid sequences provided herein.
- HDL particles serve as a preferential oxidative substrate over low density lipoprotein (LDL) particles and protect LDL particles from oxidation. HDL particles also adsorb lipopolysaccharide endotoxins, and may prevent vascular collapse seen in endotoxic shock. HDL particles additionally comprise paraoxonase (also knows as arylesterase), a 43,000 Da molecular weight, calcium-dependent ester hydrolase that catalyses the hydrolysis of a broad range of esters, such as organophosphates, as well as unsaturated aliphatic and aromatic carboxylic esters. Apo-A1 lipoprotein and paraoxonase are often found in plasma associated with HDL.
- paraoxonase also knows as arylesterase
- esters such as organophosphates, as well as unsaturated aliphatic and aromatic carboxylic esters. Apo-A1 lipoprotein and paraoxonase are often found in plasma associated with HDL.
- the inventive peptide ligand that binds to API and/or a protein complex comprising Apo-A1 lipoprotein and paraoxonase desirably comprises no more than 10 amino acids.
- the inventive peptide ligand comprises an amino acid sequence Xaa 8 -Xaa 8 -Xaa 1 -His-Xaa 1 -Xaa 3 (SEQ ID NO: 3), wherein Xaa 1 is a hydrophobic amino acid, Xaa 3 is a polar amino acid with a side chain comprising an amide, and Xaa 8 is an aromatic amino acid.
- the inventive peptide ligand comprising or consisting essentially of no more than 10 amino acids binds to API and comprises an amino acid sequence His-Xaa 8 -Xaa 9 -Xaa 1 -Xaa 10 -Xaa 2 (SEQ ID NO: 4).
- Xaa 1 is a hydrophobic amino acid
- Xaa 2 is a basic amino acid
- Xaa 8 is an aromatic amino acid
- Xaa 9 is an acidic amino acid or a hydrophobic amino acid
- Xaa 10 is a hydrophobic amino acid or His.
- the inventive peptide ligand preferably consists of amino acids in the L-conformation.
- the inventive peptide can comprise or consist essentially of an amino acid sequence HFVAPH (SEQ ID NO: 46) or HFDLHR (SEQ ID NO: 47).
- Partially purified API has been used for chronic replacement therapy in individuals with congenital API deficiency to prevent tissue damage associated with uninhibited neutrophil elastase.
- HDL particles of which Apo-A1 lipoproteins are a subunit, are predominantly involved in reverse cholesterol transport. HDL particles act as a preferential oxidative substrate over LDL particles and protect LDL particles from oxidation. HDL also adsorbs lipopolysaccharide endotoxins and may prevent vascular collapse seen in endotoxic shock.
- Paraoxonase is able to detoxify paraoxon and a number of other insecticides, e.g.
- Von Willebrand disease is the most common hereditary bleeding disorder affecting both males and females with an estimated prevalence of 1% in the population worldwide (Rodeghiero et al., Blood, 69, 454-459 (1987) and Werner et al., J. Pediatr., 123, 893-898 (1993)).
- a congenital deficiency of fVIII is responsible for hemophilia A, a severe bleeding disorder, which affects 1 in 10,000 males.
- Plasma-derived vWF and fVIII is still the mainstay of treatment for VWD and hemophilia A.
- a preferred support for use in the invention is, for example, a resin bead or membrane constructed of agarose, cellulose, dextran, glass, silica, methacrylate, hydroxyethyl methacrylate, polyacrylamide, styrenedivinylbenzene, or any composites or co-polymers thereof.
- a resin bead or membrane constructed of agarose, cellulose, dextran, glass, silica, methacrylate, hydroxyethyl methacrylate, polyacrylamide, styrenedivinylbenzene, or any composites or co-polymers thereof.
- the beads were then scooped out individually with the help of a bent needle, transferred to a well of 96-microplate (NUNC) containing Coomassie stain, and washed multiple times with warm water to remove the agarose completely.
- the bead was subsequently washed in 6.0 M guanidine-HCl for a minimum of 30 minutes, followed by 3-5 rinses of water and storage in 100% methanol before being submitted for sequencing by Edman degradation.
- a differential-subtractive immuno-detection assay entailed detecting proteins transferred onto membranes with specific HRP-conjugated polyclonal sheep anti-human vWF antibody in 1:10,000 dilution (AHP062P; Serotec) followed by exposure to chemiluminescence substrate ECLPlus. Membranes were stripped and re-probed with rabbit anti-human albumin antibody (No. A0433, Lot No. 031K4897 from Sigma) followed by secondary alkaline phosphatase-labeled goat anti rabbit antibody (Tropix). Following film development, films were aligned and dots that appeared on films for vWF and on albumin films were deemed background signal. Dots positive for vWF but not for albumin were considered positive.
- API was recovered 100% in the flow-through of D-ARQFDF (SEQ ID NO: 20) resin, and 90-95% after D-WWLHAN (SEQ ID NO: 56) chromatography.
- D-ARQFDF SEQ ID NO: 20
- SEQ ID NO: 56 D-WWLHAN
- This example illustrates the purification of API using D-AKVSKG (SEQ ID NO: 45) and D-WWLHIN (SEQ ID NO: 33) peptide ligands.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
Abstract
The invention provides an isolated or purified peptide that binds at least one plasma protein. In one embodiment, the isolated or purified peptide binds to fibrinogen, comprises no more than 10 amino acids, and comprises an amino acid sequence Xaa1-Xaa2-Xaa3-Xaa4-Xaa5, an amino acid sequence Gly-Xaa6-Arg-Xaa7, or an amino acid sequence selected from specific amino acid sequences provided herein. Alternatively, the isolated or purified protein binds to α1 proteinase inhibitor and/or a protein complex comprising Apo-A1 lipoprotein and paraoxonase. The peptide comprises no more than 10 amino acids and comprises an amino acid sequence Xaa8-Xaa8-Xaa1-His-Xaa1-Xaa3, and amino acid sequence His-Xaa8-Xaa9-Xaa1-Xaa10-Xaa2, or an amino acid sequence selected from specific amino acid sequences provided herein. In addition, the invention provides isolated or purified peptide that binds to von Willebrand Factor. The peptide comprises an amino acid sequence Xaa4-Xaa5-Xaa5, an amino acid sequence Tyr-Leu-Xaa11-Xaa4-Xaa12-Thr, or an amino acid sequence selected from specific amino acid sequences provided herein.
Description
- This patent application claims the benefit of U.S. Provisional Patent Application No. 60/372,091, filed Apr. 15, 2002.
- This invention pertains to isolated or purified peptides that bind plasma proteins and methods of use.
- Currently available processes for the commercial production of many proteins are complex, require numerous purification steps, and lack efficiency. Large scale purification of, for example, plasma-derived proteins is commonly performed by alcohol fractionation based on the methods of Cohn established over 50 years ago (Cohn et. al., J. Am. Chem. Soc, 68, 459 (1946)). Production yields for such proteins are low while manufacturing costs are high. However, affinity chromatography has been proven as an effective and efficient alternative for purifying a protein from a complex (heterogeneous) protein mixture. Affinity chromatography using peptide ligands has advantages over immunoaffinity chromatography which employs antibodies (Baumbach & Hammond, BioPharm, 5, 24-35 (1992)). Peptide ligands consist of only a few amino acids, which, unlike large murine antibodies, are not likely to cause an immune response if contamination of the purification product occurs. Peptide ligands also are more stable compared to antibodies, and can be manufactured aseptically in large quantities under Good Manufacturing Practice conditions. The interactions between peptide ligands and target proteins can be easily modified to allow mild elution conditions for separation and to provide greater control of interactions by the practitioner.
- Due to the lack of existing ligands for purification of some proteins, affinity chromatography has yet to be applied for commercial scale purification of many plasma-derived proteins. Despite advances in other protein purification techniques, many current separation methods are inefficient in avoiding contamination with undesired proteins. Accordingly, there remains a need in the art for alternative materials for the efficient separation of plasma proteins from complex mixtures. The invention provides such materials and methods of use. These and other advantages of the invention, as well as additional inventive features, will be apparent from the description of the invention provided herein.
- The invention provides an isolated or purified peptide that binds at least one plasma protein. In one embodiment, the isolated or purified peptide comprises no more than 10 amino acids and comprises an amino acid sequence Xaa1-Xaa2-Xaa3-Xaa4-Xaa5 (SEQ ID NO: 1), wherein Xaa1 is a hydrophobic amino acid, Xaa2 is a basic amino acid, Xaa3 is a polar amino acid with a side chain comprising an amide, Xaa4 is a hydrophobic amino acid or an aromatic amino acid, and Xaa5 is an acidic amino acid. Alternatively, the peptide comprises an amino acid sequence Gly-Xaa6-Arg-Xaa7 (SEQ ID NO: 2), wherein Xaa6 is Pro or Gln, and Xaa7 is any amino acid except Pro. An isolated or purified peptide comprising no more than 10 amino acids and comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 7-15, 17-19, and 28, also is provided. The isolated and purified peptide binds to fibrinogen.
- In another embodiment, the invention provides an isolated or purified protein that binds to α1 proteinase inhibitor (API) or a protein complex comprising Apo-A1 lipoprotein and paraoxonase. The peptide comprises no more than 10 amino acids and comprises an amino acid sequence Xaa8-Xaa8-Xaa1-His-Xaa1-Xaa3 (SEQ ID NO: 3), wherein Xaa1 is a hydrophobic amino acid, Xaa3 is a polar amino acid with a side chain comprising an amide, and Xaa8 is an aromatic amino acid.
- In addition, the invention provides an isolated or purified peptide that binds to API. The peptide comprises no more than 10 amino acids and comprises an amino acid sequence His-Xaa8-Xaa9-Xaa1-Xaa10-Xaa2 (SEQ ID NO: 4), wherein Xaa1 is a hydrophobic amino acid, Xaa8 is an aromatic amino acid, Xaa9 is an acidic amino acid or a hydrophobic amino acid, Xaa10 is a hydrophobic amino acid or His. Xaa2 is a basic amino acid. Alternatively, the peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 36, 38, 39, 45, 48, 54, and 55.
- Further, an isolated or purified peptide that binds to a protein complex comprising Apo-A1 lipoprotein and paraoxonase is provided. The peptide comprises no more than 10 amino acids and comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 59-62.
- An isolated or purified peptide that binds to von Willebrand Factor (vWF) also is provided. The peptide comprises no more than 6 amino acids and comprises an amino acid sequence Xaa4-Xaa5-Xaa5 (SEQ ID NO: 5), wherein Xaa4 is a hydrophobic amino acid or an aromatic amino acid, and Xaa5 is an acidic amino acid. The peptide does not comprise His, Arg, or Lys. The peptide alternatively comprises no more than 10 amino acids and comprises an amino acid sequence Tyr-Leu-Xaa11-Xaa4-Xaa12-Thr (SEQ ID NO: 6), wherein Xaa11 is an aromatic amino acid or His, Xaa4 is a hydrophobic amino acid or an aromatic amino acid, and Xaa12 is a hydrophobic amino acid or a polar amino acid. In another embodiment, the peptide comprises no more than 10 amino acids and comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 74 and SEQ ID NO: 75.
- Compositions comprising the isolated or purified peptide and methods of using the isolated or purified peptide also are provided by the invention.
- The invention provides an isolated or purified peptide (i.e., ligand) that binds to a plasma protein. In particular, the invention provides an isolated or purified peptide that binds to fibrinogen, a complex comprising Apo-A1 lipoprotein and paraoxonase, al proteinase inhibitor (API), and/or von Willebrand Factor (vWF). The isolated or purified peptide ligand is useful in a variety of contexts, including separation of plasma proteins from complex mixtures or samples, binding (e.g., immobilization) of plasma proteins to porous or non-porous surfaces, probes, sequestration of plasma proteins, coatings for medical and research devices, and therapeutics. The inventive peptide ligand preferably comprises no more than 10 amino acids (e.g., 7, 8, 9, or 10 amino acids). More preferably, the peptide comprises no more than 6 amino acids (e.g., 5, 4, or 3 amino acids). Short peptides are ideal ligands for use in many protein-binding assays and purification techniques due to cost considerations, fidelity of synthesis, and specificity in binding a target protein. In describing the invention, the standard three letter abbreviations and single letter abbreviations (in accordance with nomenclature recommendations set forth by the IUPAC-IUB Joint Commission on Biochemical Nomenclature (JCBN)) for amino acids will be used interchangeably herein.
- A great majority of peptides are composed of subunits selected from 20 naturally-occurring amino acids, 19 of which are chiral and, therefore, exist in either D- or L-configurations. Amino acids are commonly classified based on the hydrophobicity, acid or basic nature, charge, and polar characteristics of their side chains. The classes of amino acids based on the chemistry of the side chains are presented in Table 1. The peptide ligands of the invention contain neither Cys nor Met due to the inherent susceptibility of these amino acids to oxidation. In addition, since His has a pKa of 6.2 (NIST Chemistry WebBook), it can function as a hydrophobic amino acid (uncharged) as well as a charged basic amino. Gly has only a hydrogen and, therefore, is not considered as having a side chain. The polar amino acids are further classified through the presence of either a hydroxyl group (Ser or Thr) or the presence of an amide group (Asn or Gln). Naphthylalanine is an analog of the aromatic amino acid Tyr.
-
TABLE 1 Side Chain Chemistry Amino Acid Residues Acidic Asp and Glu Basic Lys, Arg, and His Polar Uncharged Ser, Thr, Asn, and Gln Hydrophobic Ala, Val, Leu, Ile, and Pro Aromatic Phe, Tyr, and Trp No Side Chain Gly - These characteristics of amino acids are important to their function as binding motifs in peptide ligands. Methods of evaluating such characteristics of individual amino acids are known in the art and described, for example, in Black and Mould, Anal. Biochem., 193, 72-82 (1991), International Patent Application WO 02/083851 and U.S. Patent Application Publication US-2003/0027751-A1. In addition to the 20 naturally-occurring amino acids commonly found in peptides, several modified amino acids are available for generation of peptides. Exemplary modified and unusual amino acids are provided in Table 2. Amino acids can be chemically modified to increase stability to proteolytic digestion, resist chemical modification under harsh conditions, modulate chemical properties such as charge, polarity, and the like.
-
TABLE 2 Symbol Amino Acid Residue Aad 2-Aminoadipic acid bAad 3-Aminoadipic acid bAla beta-Alanine, beta-Aminopropionic acid Abu 2-Aminobutyric acid 4Abu 4-Aminobutyric acid, piperidinic acid Acp 6-Aminocaproic acid Ahe 2-Aminoheptanoic acid Aib 2-Aminoisobutyric acid bAib 3-Aminoisobutyric acid Apm 2-Aminopimelic acid Dbu 2,4 Diaminobutyric acid Des Desmosine Dpm 2,2′-Diaminopimelic acid Dpr 2,3-Diaminopropionic acid EtGty N-Ethylglycine EtAsn N-Ethylasparagine Hyl Hydroxylysine aHyl allo-Hydroxylysine 3Hyp 3-Hydroxyproline 4Hyp 4-Hydroxyproline Ide Isodesmosine AIle allo-Isoleucine MeGly N-Methylglycine, sarcosine MeIle N-Methylisoleucine MeLys 6-N-Methyllysine MeVal N-Methylvaline na1′ 1-Naphthylalanine na2′ 2-Naphthylalanine Nva Norvaline Nle Norleucine Orn Ornithine - Partial or complete retro-inverso modification of peptide ligands of this invention also is possible in the context of the invention. When the modification involves more than a single peptide bond, the reversed sequence between two non-amino acid residues is comprised of the enantiomeric amino acids. Changing specific amino acid residues can confer resistance to proteolytic digestion to the inventive peptide ligand. Thus, the overall effect of the modification is to reverse the direction of the amide bond between selected residues while conserving side chain composition and three-dimensional conformation. Thus, retro-inverso ligands also will bind the targeted plasma protein and can provide additional resistance to biological degradation. Retro-inverso ligands are further discussed in, for example, Berman et al., “Synthesis and Biological Activity of Cyclic and Acyclic Partial Retro-Inverso Enkephalins,” pp. 283-286, Peptides Structure and Function, Hruby and Rich, eds., Pierce Chemical Company (1983) and Goodman and Chorev, Acc. Chem. Res., 12, 1-7 (1979).
- The invention provides an isolated or purified peptide that binds fibrinogen. Fibrinogen is the precursor of fibrin, the major protein involved in the clotting of blood. Fibrinogen is comprised of three pairs of polypeptides (Aα, Bβ, and γγ) joined by disulfide bonds, which, upon cleavage of the Aα- and Bβ-chains by thrombin, convert fibrinogen into fibrin. In one embodiment, the fibrinogen-binding peptide comprises or consists essentially of no more than 10 amino acids and comprises an amino acid sequence Xaa1-Xaa2-Xaa3-Xaa4-Xaa5 (SEQ ID NO: 1). In this respect, Xaa1 is a hydrophobic amino acid, Xaa2 is a basic amino acid, Xaa3 is a polar amino acid comprising an amide in the side chain, Xaa4 is a hydrophobic amino acid or an aromatic amino acid, and Xaa5 is an acidic amino acid. Preferably, the N-terminal amino acid of the amino acid sequence is a D-amino acid, i.e., the N-terminal amino acid is in a D-configuration. In one embodiment, Xaa1 is D-Ala, Xaa2 is Arg, Xaa3 is Asn or Gln, and Xaa5 is Asp. Preferably, the amino acid sequence is D-ARQFDF (SEQ ID NO: 20) or D-ARNIDV (SEQ ID NO: 21).
- In another embodiment, the invention provides an isolated or purified fibrinogen-binding peptide comprising an amino acid sequence Gly-Xaa6-Arg-Xaa7 (SEQ ID NO: 2), wherein Xaa6 is Pro or Gln (preferably Pro), and Xaa7 is any amino acid except Pro. The peptide comprises or consists essentially of no more than 10 amino acids. Preferably, the amino acid sequence is selected from the group consisting of GQRW (SEQ ID NO: 16), GPRYFV (SEQ ID NO: 22), GQRWAH (SEQ ID NO: 23), GPRRTS (SEQ ID NO: 24), GPRALW (SEQ ID NO: 25), GPRTHV (SEQ ID NO: 26), GPRKLD (SEQ ID NO: 27), GPRWHI (SEQ ID NO: 29), GPRELH (SEQ ID NO: 30), GPRFIE (SEQ ID NO: 31), and GQRWQE (SEQ ID NO: 32). An isolated or purified fibrinogen-binding peptide comprising or consisting essentially of no more than 10 amino acids and comprising an amino acid sequence selected from the group consisting of HWQ (SEQ ID NO: 7), FDI (SEQ ID NO: 8), HNP (SEQ ID NO: 9), HNK (SEQ ID NO: 10), HWR (SEQ ID NO: 11), WEW (SEQ ID NO: 12), KFF (SEQ ID NO: 13), KKY (SEQ ID NO: 14), PGY (SEQ ID NO: 15), PWFIPG (SEQ ID NO: 17), WEIYQT (SEQ ID NO: 18), WNGQPA (SEQ ID NO: 19), and GPRPNI (SEQ ID NO: 28) also is contemplated in the context of the invention. When the amino acid sequence is PWFIPG (SEQ ID NO: 17), WEIYQT (SEQ ID NO: 18), or WNGQPA (SEQ ID NO: 19), the amino acid sequence comprises a D-amino acid at the N-terminus.
- The peptide ligand of the invention is “isolated or purified.” By “isolated” is meant removed from its natural state or resulting from synthesis. By “purified” is meant any degree of purification of the peptide ligand from its natural state or from its state of synthesis. Desirably, contaminants, such as other proteinaceous and nonproteinaceous components, which could interfere with the diagnostic and therapeutic applications of the inventive plasma protein-binding peptide ligand, are removed. It will be appreciated that the complete (absolute) isolation or purification of the peptide is not required.
- In certain embodiments, the isolated or purified peptide of the invention comprises or consists essentially of no more than 10 amino acids. Accordingly, a peptide ligand can comprise amino acids in addition to the amino acid sequence specifically set forth herein and designated a SEQ ID NO. For example, the fibrinogen-binding peptide of the invention can consist essentially of 10 amino acids, six of which are ARQFDF (SEQ ID NO: 20), a plasma protein (e.g., fibrinogen)-binding motif. The remaining one, two, three, or four amino acids can be on the N- or, preferably, the C-terminus of the plasma protein-binding motif and should not prevent contact of the plasma protein-binding motif with the target plasma protein. The remaining amino acids can, for instance, serve as a linker to a support, stabilize peptide conformation, modulate binding specificity or affinity, and/or comprise a second binding motif. However, the isolated or purified peptide can consist or consist essentially of the plasma protein-binding motif. For example, the fibrinogen-binding peptide can consist essentially of the amino acid sequence ARQFDF (SEQ ID NO: 20).
- The isolated or purified peptide of the invention binds to one or more plasma proteins, namely fibrinogen, API, a complex comprising Apo-A1 lipoprotein and paraoxonase, and/or vWF. In other words, the isolated or purified peptide comprises or consists essentially of an amino acid sequence that binds to a plasma protein (in, for example, a mixed sample) with moderate to strong avidity under controlled conditions of pH, ionic strength, and solvent composition. As described above, the binding avidity can be modulated by the presence of amino acids adjacent to the plasma protein-binding motif. Alternatively, binding avidity can be decreased or increased by substituting single amino acids and/or by terminal deletion of amino acids in the amino acid sequences provided herein. In addition, varying the pH, ionic strength, and components of a composition comprising the isolated or purified peptide can modify binding avidity. It is generally preferred that the inventive peptide ligand selectively binds to one of the aforementioned plasma proteins to the exclusion of other proteins. It is not required that the inventive peptide ligand bind to the entire, intact plasma protein, although this may be preferred in some embodiments of the invention. It can be advantageous for the inventive peptide ligand to bind to a subunit of a plasma protein (e.g., a site involved in catalysis or protein-protein interaction). In this respect, the inventive peptide ligand ideally binds to a site on the plasma protein that is unique to the plasma protein in order to retain specificity of the inventive peptide for the plasma protein. For example, it is preferred that the isolated or purified peptide binds to the plasma protein with at least two-fold (e.g., three-fold, five-fold, or ten-fold) greater avidity than the isolated or purified peptide binds to other proteins. Likewise, the inventive peptide ligand can bind to a complex, e.g., a protein complex, that comprises the plasma protein. For example, factor VIII (fVIII) in plasma is often associated with vWF. The isolated or purified peptide can bind to such a plasma protein complex, if desired.
- The invention further provides an isolated or purified peptide that binds to API and/or a protein complex comprising Apo-A1 lipoprotein and paraoxonase. API is a 53,000 Da molecular weight glycoprotein that circulates in plasma at an approximate concentration of 1.5 mg/ml. API controls tissue destruction through inhibition of endogenous serine proteinase activity, specifically neutrophil elastase, and is the most concentrated serine proteinase inhibitor in blood plasma (Johnson et al., Biochem. Biophys. Res. Comm., 72, 33-39 (1976)). Apo-A1 lipoprotein is a component of high density lipoprotein (HDL) particles found in mammalian blood and lymph circulation. HDL particles are predominantly involved in reverse cholesterol transport. HDL particles serve as a preferential oxidative substrate over low density lipoprotein (LDL) particles and protect LDL particles from oxidation. HDL particles also adsorb lipopolysaccharide endotoxins, and may prevent vascular collapse seen in endotoxic shock. HDL particles additionally comprise paraoxonase (also knows as arylesterase), a 43,000 Da molecular weight, calcium-dependent ester hydrolase that catalyses the hydrolysis of a broad range of esters, such as organophosphates, as well as unsaturated aliphatic and aromatic carboxylic esters. Apo-A1 lipoprotein and paraoxonase are often found in plasma associated with HDL.
- The inventive peptide ligand that binds to API and/or a protein complex comprising Apo-A1 lipoprotein and paraoxonase desirably comprises no more than 10 amino acids. Furthermore, the inventive peptide ligand comprises an amino acid sequence Xaa8-Xaa8-Xaa1-His-Xaa1-Xaa3 (SEQ ID NO: 3), wherein Xaa1 is a hydrophobic amino acid, Xaa3 is a polar amino acid with a side chain comprising an amide, and Xaa8 is an aromatic amino acid. Preferably, Xaa8 at position 1 of the amino acid sequence of SEQ ID NO.: 3 is Trp, Tyr, 1-naphthylalanine (na1′), or 2-naphthylalanine (na2′). Optionally, Xaa8 at position 1 is a D-amino acid. Xaa8 at position 2 of the amino acid sequence of SEQ ID NO: 3 preferably is Trp, Tyr, na1′, or na2′, while Xaa1 at position 3 preferably is Leu. Xaa1 at position 5 preferably is Ile. Also preferably, Xaa3 at position 6 of the amino acid sequence of SEQ ID NO: 3 is Asn or Gln. For example, the isolated or purified peptide can comprise or consist essentially of one of the following amino acid sequences: WWLHIN (SEQ ID NO: 33), YWLHIN (SEQ ID NO: 34), WYLHIN (SEQ ID NO: 35), FWLHIN (SEQ ID NO: 37), na1′WLHIN (SEQ ID NO: 40), na2′WLHIN (SEQ ID NO: 41), Wna2′LHIN (SEQ ID NO: 42), WLLHIN (SEQ ID NO: 43), WWLHIA (SEQ ID NO: 44), na1′YLHIN (SEQ ID NO: 49), na2′na1′LHIN (SEQ ID NO: 50), na1′na1′LHIN (SEQ ID NO: 51), na2′YLHIN (SEQ ID NO: 52), na1′na2′LHIN (SEQ ID NO: 53), WWLHAN (SEQ ID NO: 56), YYLHIN (SEQ ID NO: 57), WFLHIN (SEQ ID NO: 58), WWAHIN (SEQ ID NO: 61), or WWLHIA (SEQ ID NO: 63).
- In another embodiment, the inventive peptide ligand comprising or consisting essentially of no more than 10 amino acids binds to API and comprises an amino acid sequence His-Xaa8-Xaa9-Xaa1-Xaa10-Xaa2 (SEQ ID NO: 4). In this embodiment, Xaa1 is a hydrophobic amino acid, Xaa2 is a basic amino acid, Xaa8 is an aromatic amino acid, Xaa9 is an acidic amino acid or a hydrophobic amino acid, and Xaa10 is a hydrophobic amino acid or His. The inventive peptide ligand preferably consists of amino acids in the L-conformation. For example, the inventive peptide can comprise or consist essentially of an amino acid sequence HFVAPH (SEQ ID NO: 46) or HFDLHR (SEQ ID NO: 47).
- In another embodiment, the API-binding isolated or purified peptide comprises an amino acid sequence WWLFIN (SEQ ID NO: 36), WWLRIN (SEQ ID NO: 38), WWLLIN (SEQ ID NO: 39), AKVSKG (SEQ ID NO: 45), Tna1′LHIN (SEQ ID NO: 48), PLRGYY (SEQ ID NO: 54), or WKVYAD (SEQ ID NO: 55). Ideally, the amino acid sequence comprises an N-terminal amino acid that is a D-amino acid.
- Further, an isolated or purified peptide that binds to a protein complex comprising Apo-A1 lipoprotein and paraoxonase is provided. The inventive peptide ligand comprises or consists essentially of no more than 10 amino acids and comprises an amino acid sequence selected from the group consisting of AWLHIN (SEQ ID NO: 59), WALHIN (SEQ ID NO: 60), WWAHIN (SEQ ID NO: 61), and WWLAIN (SEQ ID NO: 62). The inventive peptide ligand can bind to the Apo-A1 lipoprotein portion of the complex, the paraoxonase portion of the complex, or the intact HDL particle complex comprising both proteins. In binding paraoxonase, the amino acid sequence preferably is na1′WLHIN (SEQ ID NO: 40). To bind Apo-A1 lipoprotein, the amino acid sequence preferably is WFLHIN (SEQ ID NO: 58) or WWLHAN (SEQ ID NO: 63).
- In another embodiment of the invention, the isolated or purified peptide binds to vWF. In that fVIII is typically found in circulation complexed with vWF, the isolated or purified peptide can bind to a protein complex comprising vWF and fVIII. vWF mediates platelet adhesion to injured blood vessels through the interaction of specific domains with GPIb and GPIIb/IIIa receptors located on platelets and endothelium. It also serves as a carrier for procoagulant fVIII in circulating blood, where the two molecules are present as the vWF/fVIII complex. In one embodiment, the isolated or purified peptide comprises or consists essentially of no more than 6 amino acids and comprises an amino acid sequence Xaa4-Xaa5-Xaa5 (SEQ ID NO: 5), wherein Xaa4 is a hydrophobic amino acid or an aromatic amino acid, and Xaa5 is an acidic amino acid. The inventive peptide ligand of this embodiment does not contain basic amino acids (e.g., His, Arg, or Lys). Preferably, Xaa5 is Asp or Glu. Optionally, the isolated or purified peptide comprises or consists essentially of the amino acid sequence ADENDL (SEQ ID NO: 64), AEEESP (SEQ ID NO: 65), EADna2′ED (SEQ ID NO: 66), EIFWDE (SEQ ID NO: 68), FSYDED (SEQ ID NO: 69), LEDna2′EE (SEQ ID NO: 70), PLVEDD (SEQ ID NO: 71), WDEPFY (SEQ ID NO: 72), YVDEDD (SEQ ID NO: 73), or WEEPEQ (SEQ ID NO: 11-1).
- The vWF-binding inventive peptide ligand alternatively comprises or consists essentially of no more than 10 amino acids and comprises an amino acid sequence Tyr-Leu-Xaa1-Xaa4-Xaa12-Thr (SEQ ID NO: 6), wherein Xaa11 is an aromatic amino acid or His, Xaa4 is a hydrophobic amino acid or an aromatic amino acid, and Xaa12 is a hydrophobic amino acid or a polar amino acid. Desirably, Xaa1 is His or Tyr, Xaa4 is Tyr or Ala, and Xaa12 is Gln or Leu. For example, the isolated or purified peptide of the invention can comprise or consist essentially of the amino acid sequence YLHYQT (SEQ ID NO: 74) or YLYALT (SEQ ID NO: 75)
- In another embodiment, the vWF-binding inventive peptide ligand comprises or consists essentially of no more than 10 amino acids and comprises the amino acid sequence EDSWDV (SEQ ID NO: 67), YHLGWL (SEQ ID NO: 76) or QWFPEK (SEQ ID NO: 77). Other vWF-binding inventive peptide ligands contemplated in the context of the invention comprise or consist essentially of the following amino acid sequences: AAHDna2′W (SEQ ID NO: 78), APWPHD (SEQ ID NO: 79), ANWGKE (SEQ ID NO: 80), AWKWSA (SEQ ID NO: 81), DQGLLR (SEQ ID NO: 82), EAVSRF (SEQ ID NO: 83), IEna2′EGR (SEQ ID NO: 84), IFFSQS (SEQ ID NO: 85), KDHNna2′E (SEQ ID NO: 86), LGRLGna2′ (SEQ ID NO: 87), LPRADW (SEQ ID NO: 88), LSQTWA (SEQ ID NO: 89), LPELYH (SEQ ID NO: 90), LVRDKV (SEQ ID NO: 91), NIIGHV (SEQ ID NO: 92), NADna2′AE (SEQ ID NO: 93), PAKHSE (SEQ ID NO: 94), Pna2′PTVA (SEQ ID NO: 95), PVGRFE (SEQ ID NO: 96), PVHKLN (SEQ ID NO: 97), QYYTGR (SEQ ID NO: 98), RDVNRY (SEQ ID NO: 99), REALWI (SEQ ID NO: 100), REPQSD (SEQ ID NO: 101), RIFNLV (SEQ ID NO: 102), SSQna2′NK (SEQ ID NO: 103), SNVDGR (SEQ ID NO: 104), SYHASL (SEQ ID NO: 105), VATKLL (SEQ ID NO: 106), VLARQL (SEQ ID NO: 107), VGHFNF (SEQ ID NO: 108), VSKWGG (SEQ ID NO: 109), VYWDGT (SEQ ID NO: 110), WLTSSA (SEQ ID NO: 112), WPKAPV (SEQ ID NO: 113), WTNWQS (SEQ ID NO: 114), YAPVRF (SEQ ID NO: 115), YKQLRG (SEQ ID NO: 116), YPHna2′VV (SEQ ID NO: 117), YQSNWV (SEQ ID NO: 118), or YYVTSE (SEQ ID NO: 119).
- The isolated or purified peptide can be combined with carrier to form a composition. Any suitable carrier can be used, and several carriers suitable for detection methods, protein library screening, affinity chromatography preparation, and therapeutics are known in the art. The characteristics of the carrier will depend on the particular embodiment of the invention. For example, the carrier can be a liquid carrier such as, for example, water, petroleum, physiological saline, bacteriostatic water, Cremophor ELTM (BASF, Parsippany, N.J.), phosphate buffered saline (PBS), or oils. The composition and/or carrier can include diluents, fillers, salts, buffers, stabilizers, solubilizers, preservatives, and/or other appropriate materials. The composition can comprise the target protein, if desired. The composition need not be a liquid, but also can be in the form of a gel, cream, aerosol, and the like. Compositions and carriers, including pharmaceutically-acceptable compositions and carriers, are further described in, e.g., Urquhart et al., Lancet, 16, 367 (1980), Lieberman et al., Pharmaceutical Dosage Forms—Disperse Systems, 2nd ed., vol. 3, (1998), Ansel et al., Pharmaceutical Dosage Forms & Drug Delivery Systems, 7th ed. (2000), Remington's Pharmaceutical Sciences, and U.S. Pat. Nos. 5,708,025 and 5,994,106.
- The isolated or purified peptide of the invention can be isolated from nature or synthetically generated. Several methods are available for identifying and isolating the inventive peptide ligand from a natural source. For example, reverse phase and ion exchange chromatography, precipitation, and affinity chromatography using ligands (such as antibodies) can be used to obtain the isolated or purified peptide. Monoclonal antibodies that specifically bind the inventive peptide ligand can be generated using standard immunization techniques described in, for example, Harlow and Lane, Antibodies, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. (1988). Use of such antibodies to detect and isolate target proteins from a complex mixture is known in the art and requires only routine laboratory techniques. The inventive peptide ligand can be generated by recombinant means by synthesizing a nucleic acid sequence that encodes a desired amino acid sequence, such as one of the amino acid sequences described herein. The nucleic acid sequence is introduced into bacterial or mammalian cells (bioreactors) to achieve protein production. Alternatively, the inventive peptide ligand can be generated synthetically using methods such as those as described in the working examples provided-herein. Likewise, candidate peptide ligands can be screened for binding to one or more plasma proteins using methods such as those set forth in the working examples.
- The peptide ligands of the invention are appropriate for use in research, diagnostic, and therapeutic settings. The targets for the inventive peptide ligand, e.g., fibrinogen, API, Apo-A1 lipoprotein and paraoxonase, and/or vWF, are medically-relevant plasma proteins with a wide array of applications. Fibrinogen has been produced commercially for use in hemostatic preparations, normally marketed as fibrin sealants or fibrin glues, to decrease blood loss and the time to hemostasis during surgery or following critical injuries. Many current processes for production of fibrinogen are complex, require numerous purification steps, and often result in impure concentrates.
- Partially purified API (PROLASTIN, Bayer) has been used for chronic replacement therapy in individuals with congenital API deficiency to prevent tissue damage associated with uninhibited neutrophil elastase. HDL particles, of which Apo-A1 lipoproteins are a subunit, are predominantly involved in reverse cholesterol transport. HDL particles act as a preferential oxidative substrate over LDL particles and protect LDL particles from oxidation. HDL also adsorbs lipopolysaccharide endotoxins and may prevent vascular collapse seen in endotoxic shock. Paraoxonase is able to detoxify paraoxon and a number of other insecticides, e.g. diazonin, as well as the potent nerve gases sarin and soman that target acetylcholinesterase. In addition, one possible substrate for paraoxonase is oxidized LDL (Aviram et al., Arterioscler. Thromb. Vasc. Biol., 18(10), 1617-24 (1998); Mackness et al., FEBS Lett., 423(1), 57-60 (1998); and Costa et al., Ann. Rev Med., 54, 371-92 (2003)). Paraoxonase has been shown both to prevent formation of oxidized LDL and to hydrolyze LDL-derived oxidized phospholipids. Since accumulation of oxidized LDL is one of the key factors in development of atherosclerosis, paraoxonase activity may correlate with development of this disease. Thus, infusion of paraoxonase can prevent or reverse atherosclerotic plaque formation, as well as provide protection against organophosphate poisoning.
- vWF is essential for the normal arrest of bleeding after tissue injury (hemostasis). Without binding to vWF, the biological half-life of fVIII is reduced from approximately 14 hours to about 3 hours. Hence, qualitative or quantitative abnormalities of plasma vWF results in a mild bleeding disorder, which can remain undiagnosed for many years. Very low levels of vWF is associated with low levels of fVIII, which causes symptoms similar to hemophilia A (Sadler et al., Journal of Biological Chemistry, 266(34), 22777-2278 (1991); Ruggeri et al., FASEB J, 7(2), 308-316 (1993); Ginsburg, Thrombosis and Haemostasis, 82 (2), 585-591 (1999); and Federici et al., Haemophilia, 4, 654-660 (1998)). Von Willebrand disease (VWD) is the most common hereditary bleeding disorder affecting both males and females with an estimated prevalence of 1% in the population worldwide (Rodeghiero et al., Blood, 69, 454-459 (1987) and Werner et al., J. Pediatr., 123, 893-898 (1993)). A congenital deficiency of fVIII is responsible for hemophilia A, a severe bleeding disorder, which affects 1 in 10,000 males. Plasma-derived vWF and fVIII is still the mainstay of treatment for VWD and hemophilia A.
- The peptide ligands of the invention are ideal probes for quantifying, detecting, and characterizing the plasma proteins described herein. The inventive peptide ligands can be engineered to comprise radiolabelled amino acids or can be conjugated to a marker to facilitate detection. Thus, the inventive peptide ligand binds a target plasma protein, and detection of the inventive peptide ligand indicates the presence of the plasma protein. On the other hand, plasma proteins can be captured by the inventive peptide ligand for detection, quantification, or characterization using other means such as mass spectroscopy or Western Blot. Preferred methods of characterizing a target, such as a plasma protein, are described in U.S. Provisional Patent Application No. 60/372,091.
- The inventive peptide ligand also is suitable for use in affinity chromatography protocols to purify, separate, or isolate plasma proteins from complex protein mixtures, such as plasma and Cohn fractions, for research or therapeutic applications. Accordingly, the invention provides a method of separating, isolating, purifying, characterizing, identifying, or quantifying a plasma protein or complex thereof (e.g., fibrinogen, API, a complex comprising Apo-A1 lipoprotein and paraoxonase, and/or vWF) in a sample. The method comprises contacting a sample comprising the plasma protein (e.g., fibrinogen, API, a complex comprising Apo-A1 lipoprotein and paraoxonase, and/or vWF) with the isolated or purified peptide to form a plasma protein-peptide complex. The method further comprises separating, isolating, purifying, characterizing, identifying, or quantifying the plasma protein-peptide complex. To facilitate separation of the plasma protein-peptide complex from the sample, the inventive peptide ligand preferably is attached to a support. Examples of suitable supports include, but are not limited to insoluble support matrices such as a naturally occurring polymer, for example, a polypeptide or protein, such as cross linked albumin or a polysaccharide such as agarose, alginate, carrageenan, chitin, cellulose, dextran or starch; synthetic polymers such as polyacrylamide, polystyrene, polyacrolein, polyvinyl alcohol, polymethylacrylate, polyester, perfluorocarbon; inorganic compounds such as silica, glass, kieselguhr, zirconia, alumina, iron oxide or other metal oxides; or co-polymers consisting of any combination of two, or more of a naturally occurring polymer (e.g., polysaccharide, or protein), synthetic polymer or inorganic compounds. Such insoluble supports can be subjected to cross linking or other treatments to increase their physical or chemical stability and can be formed into various shapes including fibers, sheets, rods, or membranes. Also appropriate are soluble support matrices comprising polymers such as dextran, polyethylene glycol, polyvinyl alcohol or hydrolysed starch which provide affinity-ligand matrix conjugates for use in liquid partitioning; or supports comprising compounds such as perfluorodecalin which provide affinity-ligand matrix conjugates for use in the formation of affinity emulsions. The support can be modified by treatment with an activating agent. In one embodiment, the support is any compound or material whether particulate or non-particulate, soluble or insoluble, porous or non-porous which can be used to form a novel ligand-matrix conjugate and which provides a convenient means of separating the inventive peptide ligand from solutes in a contacting solution. The support also can be nylon, cotton, or other material commonly used in bandages, patches, and other wound coverings. A preferred support for use in the invention is, for example, a resin bead or membrane constructed of agarose, cellulose, dextran, glass, silica, methacrylate, hydroxyethyl methacrylate, polyacrylamide, styrenedivinylbenzene, or any composites or co-polymers thereof. Many affinity chromatography procedures for both small and large scale isolation of target proteins, as well as methods of adhering peptides to solid supports, are known in the art.
- In one embodiment, a plasma protein is removed from a sample for detection and characterization. For example, the inventive peptide ligand is immobilized on a support (e.g., a resin bead), and the peptide-support complex is affixed in an array within a porous first matrix, such as an agarose gel. Plasma is brought into contact with the ligand-support complexes. In one aspect, the plasma sample percolates through the porous first matrix to effect contact between peptide-support complex and plasma protein. Alternatively, the plasma sample is contacted with the peptide-support complexes prior to immobilization in the porous first matrix. The inventive peptide ligand captures the desired plasma protein and separates the plasma protein from the remainder of sample. The plasma protein is subsequently dissociated from the peptide-support complex through capillary action of a transfer solution moving through the porous first matrix and past the plasma protein-peptide-support complexes. The transfer solution carries the eluted plasma protein from the porous first matrix to a second matrix, such as a membrane, onto which the plasma protein adheres. Once transferred to the membrane, the plasma protein can be detected. In a clinical setting, detecting the presence or absence of specific plasma proteins can indicate an underlying medical condition, such as a bleeding disorder (fibrinogen or vWF deficiency) or an increased risk of atherosclerosis (paraoxonase deficiency). Accordingly, the invention provides a diagnostic assay comprising the inventive peptide ligand in combination with a means of detecting the plasma protein or plasma protein complex.
- The binding of the inventive peptide ligand to a plasma protein also can be exploited to attract or sequester a plasma protein to a location on or within a mammal. The inventive peptide ligand, strategically applied, can attract and capture plasma protein in a region of the body in need thereof, such as wound or other physical insult. On the other hand, an implant or covering comprising the inventive peptide ligand can sequester plasma protein, thereby removing plasma protein from circulation. The invention provides a medical device or implant comprising a substrate comprising the inventive peptide ligand, which can be infused into the substrate or coated thereon. Devices and implants can be composed of any suitable physiologically-acceptable material. Examples of suitable materials for producing non-biodegradable administration devices or implants include hydroxapatite, bioglass, aluminates, other ceramics, cotton, nylon, and the like. Topical administration of the inventive peptide ligands is particularly preferred and can be achieved using, for example, a drug reservoir, transdermal patch device, bandage, or any of the foregoing in combination with a cream, ointment, or salve comprising the inventive peptide ligand. Examples of suitable matrixes include those described elsewhere herein and in U.S. Pat. No. 5,270,300. Implants or devices can take the form of a matrix, such as a sponge, tube, telfa pad, pad, powder, or nanoparticle, which can release the inventive peptide ligand as dictated by the practitioner. In certain embodiments, the inventive peptide ligand is applied to a wound to promote clot formation or minimize harmful inflammatory responses, optionally in conjunction with a wound dressing. Likewise, the inventive peptide ligand can be incorporated into in situ tissue scaffolding to reduce scar healing and promote normal wound healing. The inventive peptide also can be incorporated into artificial skin graft and biodegradable matrices including polyglycolic acid and spider silk protein.
- The invention provides a method for exploiting the biological activity of plasma proteins in the therapeutic or prophylactic treatment of wounds, bleeding disorders, localized inflammation, metabolite toxicity, and the like. For example, the invention provides a method of promoting clot formation by administering to a mammal the inventive peptide ligand that binds to fibrinogen, which captures fibrinogen in the area of, for example, a wound, thereby promoting clot formation and enhancing wound healing in the mammal. Wounds suitable for treatment with the inventive peptide ligand include any lesion or injury to any portion of the body of a mammal including burns, trauma-induced injuries including excisional wounds, ulcers, post-surgical injuries pressure sores, bedsores, and conditions related to diabetes and poor circulation. Additionally or alternatively, a method of enhancing wound healing can comprise administering to a mammal the inventive peptide ligand that binds vWF. Immobilized vWF will bind platelets to promote clot formation. In addition, co-localization of fVIII will stimulate coagulation. A mixture of ligands that bind vWF and ligands that bind fibrinogen will bind both fibrinogen and vWF, thereby accelerating clot formation. For example, ARQFDF (SEQ ID NO: 20) can be synthesized and coupled through a linker to a macroporous support, e.g., an absorbable bandage, at a density of about 1 μmol to about 50 μmol (e.g., about 10, 15, 20, 25, 30, 35, 40, or 45 μmol) of peptide/ml of swollen bandage. Similarly, EADna2′ED (SEQ ID NO: 66) can be synthesized and then coupled to a macroporous bandage at a similar density of peptide/ml of swollen bandage. The peptide densities for both ligands are adjusted when coupled to non-porous support materials to provide a surface density of about 0.1 μmol to about 10 μmol (e.g., about 2, 3, 4, 5, 6, 7, 8, or 9 μmol) per square meter of surface area of the support.
- In a method of therapeutically or prophylactically treating tissue damage (optionally due to uncontrolled lymphocyte elastase activity), the inventive peptide ligands that bind API protein can be administered to a mammal to attract API protein to a tissue suffering from or at risk of suffering from tissue damage, thereby treating the tissue for damage therapeutically or prophylactically. Lung tissue is particularly susceptible to damage caused by uncontrolled lymphocyte elastase activity, which can lead to emphysema. Ligands that bind HDL may be localized to areas of atherosclerotic plaque formation, thereby concentrating HDL and accelerating the reverse transport of cholesterol and protecting against further oxidative damage of LDL through the arylesterase activity of paraoxonase.
- The invention further provides a method for increasing the half-life of proteins and pro-drugs in circulation. Peptide ligands of the invention that bind fibrinogen, vWF, and/or HDL can be synthesized onto, or attached to, a protein, pro-drug or other moiety such that the peptide ligand facilitates the association of the desired compound to fibrinogen, vWF, and/or HDL in the circulation. The large size of these molecules will prevent the removal of the attached low (e.g., less than 25,000 Dalton) molecular weight proteins and pro-drugs from being rapidly filtered by the kidney and voided in the urine.
- The following examples further illustrate the invention but, of course, should not be construed as in any way limiting its scope. The following materials were used in the examples: lyophilized human plasma (Accuclot™ Reference Plasma, Normal, Cat. No. A7432, Lot No.: 090K6513 from Sigma); lyophilized control normal plasma (Art. No. 823542, Lot No. 40640 from Chromogenix); factor VIII-deficient plasma (FACTOR VIII D-1, Lot No. 031K6117, from Sigma); American Red Cross (ARC) human pooled plasma of 30 units (lot 080902); rabbit anti-human fibrinogen polyclonal antibody (Code No. PO455; Dako Corp.); goat anti-rabbit HRP-conjugated IgG (Cat. No. 074-1506; KPL); ARC fibrinogen (Lot No. 28309022A; Baxter, Glendale, Calif.); HRP-labeled goat anti-human API antibody (Cat. No. 55236, Lot No. 01140; ICN); ARC API protein (Lot No. 6111009 and Lot No. 6112001, Kamada, Israel); Kodak X-OMAT; Kodak BIOMAX ME; HRP-conjugated polyclonal sheep anti-human vWF-antibody (Lot No. AHP062P, Serotec); primary monoclonal anti-vWF antibody (Lot No. 101.104, Enzyme Research); rabbit anti-human albumin antibody (No. A0433, Lot No. 031K4897, Sigma); goat anti-rabbit-PA-se (Tropix); ECL Plus (Pierce); DEPFMU (di-ethyl phospho 6,8-difluoro-4-methylumbelliferyl), Tergitol (Sigma); GelBond® film sheets (Cat. No. 53749; BMA); and KPL chemiluminescent substrate (Amersham). All chemicals were reagent grade of better. Combinatorial libraries and resins were synthesized at Peptides International, Inc., Louisville, Ky. All experiments and chromatographic evaluations were performed at room temperature, unless specified otherwise.
- This example describes a method for generating an isolated or purified peptide of the invention.
- A 3-mer, 4-mer, and 6-mer peptide library was synthesized onto Toyopearl-AF Amino 650M resin (Tosohaas, Montgomeryville, Pa.). The size of the resin beads ranged from 60-130 mm per bead. Initial substitution of the starting resin was achieved by coupling of a mixture of Fmoc-Ala-OH and Boc-Ala-OH (1:3.8 molar ratio). After coupling, the Boc protecting group was removed with neat TFA in full. The resulting deprotected amino groups were then acetylated. Peptide chains were assembled via the remaining Fmoc-Ala-OH sites on the resin bead. Standard Fmoc synthetic strategies were employed.
- In a typical experiment, six grams of Fmoc-Ala-(Ac-Ala-)Toyopearl Resin was deprotected with 20% piperidine/DMF (2×20 min), then washed with DMF (8 times) and equally divided into 18 separate reaction vessels. In each separate vessel, a single Fmoc-amino acid was coupled to the resin (BOP/NMM, 5-10 told excess) for 4-7 hours. The individual resins were washed and combined using the “split/mix” library technique (Furka et al., Int. J. Peptide Protein Res., 37, 487-493 (1991); Lam et al., Nature, 354, 82-84 (1991); International Patent Application WO 92/00091 (1992); U.S. Pat. No. 5,010,175; U.S. Pat. No. 5,133,866; and U.S. Pat. No. 5,498,538). The cycle of deprotection and coupling was repeated until the amino acid sequence was completed (six cycles for a hexamer library). The final Fmoc was removed from peptide resins using 20% piperidine/DMF in separate reaction vessels during the last coupling cycle. Side-chain protecting groups were removed with TFA treatment (TFA:H20:Phenol, 90:5:5) for 2 hours. Resins were washed extensively and dried under a vacuum. Peptide densities achieved were typically in the range of 0.06-0.12 mmol/g of resin.
- Sequencing and peptide composition of peptide ligand-resin bead complexes were confirmed, and the degree of substitution of the resin was calculated by quantitative amino acid analysis at Commonwealth Biotechnologies, Inc., Richmond, Va. Sequencing was performed at Protein Technologies Laboratories, Texas A&M University, by Edman degradation using a Hewlett PackardG1005A.
- Following the protocol of Jentoft et al. (Meth. Enzymol., 91, 570-579 (1983)), fibrinogen was labeled via reductive C14-methylation. The C14-labeled formaldehyde was obtained from ICN (Cat. No. 1723783). ARC human fibrinogen (Lot No. 28309022A), manufactured at Hyland Baxter Facility (Glendale, Calif.) from cryo-precipitate, was used for the radiolabeling.
- Specifically, 0.45 mg of fibrinogen in 1.0 ml PBS or 2 mg of API in 0.5 ml PBS was mixed with 50 ml or 25 ml of NaCHBH3, respectively. After careful mixing, 3 ml of C14-labeled formaldehyde (57 mCi/mmol) was added and gently stirred for 2 hours at room temperature. The non-incorporated C14-labeled formaldehyde was separated from the C14-labeled fibrinogen or C14-labeled API by dialysis against 0.15 M NaCl, 0.020 M sodium citrate, pH 7.5, using Slide-A-Lyzer Cassette (MWCO 10,000) dialysis bags from Pierce. The dialysis was performed overnight at 4° C. The C14-labeled proteins were stored in aliquots at −80° C. The fibrinogen and API concentrations were quantified using optical density readings at 280 nm and an extinction coefficient of 15.0 or 5.0 for a 1% solution, respectively. The resulting concentrations were about 1 mM for C14-labeled fibrinogen and 30 mM for 14C-labeled API.
- The number of disintegrations per minute (DPM) of radioactive samples was determined using a Beckman LS 3801 Scintillation Analyzer and ScintiVerse II (SX 12-4; Fisher). Values of DPM were corrected for the background of the liquid scintillation counter (30-40 DPM) unless specified otherwise.
- Peptide libraries attached to Toyopearl-AF Amino 650M resin or Tentagel resin were evaluated with 14C-labeled fibrinogen and API. All steps were performed at room temperature. Specifically, 20 mg of Toyopearl resin beads or 40 mg of Tentagel resin beads were suspended in 20% methanol for a minimum of 2 hours in 15 ml conical polypropylene tubes (Corning). After rinsing with distilled water, the resin beads were equilibrated in 0.15 M NaCl, 0.020 M sodium citrate, pH 7.3. The resin beads were then blocked for 2 hours with 1% casein (Sigma) in 0.15M NaCl, 0.020M sodium citrate, pH 7.3. Following blocking, the resin beads were centrifuged and the supernatant removed. A solution containing 1 mM of C14-labeled fibrinogen or 30 μM of C14-labeled API was applied to the resin beads in the blocking solution in the presence of 0.1% Tween-20 (Sigma). The materials were incubated for 2 hours. The resin beads were washed with 0.15 M NaCl, 0.020 M sodium citrate, 0.05% Tween-20, pH 7.3, in a batch method (fibrinogen ligands) or in disposable BioRad 10 ml columns (API ligands) until radiation counts reached the background level of less than 40 DPM. The resin beads were divided into separate tubes to obtain approximately 5-10 mg of resin beads per sheet. This was accomplished by mixing each aliquot of resin beads with 20-22 ml of 1% low melting agarose solution (Sigma) at less than 40° C., and rapidly pouring the mixture onto GelBond® film sheets (BMA Cat. No. 53749, 16×18 cm; Cat. No. 53759, 12.5×24.5 cm). Spreading of the resin beads to the edge of the gel sheets was prevented by creating frames (about 23 cm×about 10 cm or about 15 cm×about 15 cm) with several layers of masking tape. About 20-22 ml of resin bead-agarose mixture was plated on each GelBond sheet. Special care was taken to spread the beads in an even monolayer to facilitate identification and isolation of individual “hot” beads. The agarose gel was then air-dried overnight and placed, bead side down, on X-ray film (Kodak Biomax MR). The agarose and autoradiography film were exposed for 4-14 days followed by a second exposure of 7 days in an about 20 cm×about 25 cm stainless steel cassette. Afterwards, the films were taped together and marked with several staple holes to ensure proper alignment of beads in agarose to film. After the films were developed, the positive beads that appeared on both films were identified under the microscope and picked by aligning the developed film(s) and agarose gel via the staple holes. Beads to be sequenced were carefully picked by cutting a square trench around the bead with a scalpel, and hydrating this area with distilled water. The beads were then scooped out individually with the help of a bent needle, transferred to a well of 96-microplate (NUNC) containing Coomassie stain, and washed multiple times with warm water to remove the agarose completely. The bead was subsequently washed in 6.0 M guanidine-HCl for a minimum of 30 minutes, followed by 3-5 rinses of water and storage in 100% methanol before being submitted for sequencing by Edman degradation.
- Each screening step was performed at room temperature for 1 hour in 1.5 ml Eppendorf tubes with gentle rotation. After each step of the screening method, resin beads were concentrated by centrifugation at 14,000 g for 1 minute to exchange solution. One milligram of resin was suspended in 100 ml of 20% methanol. After washing with 500 ml of 0.12 M NaCl, 0.020M sodium chloride, 0.1% (v/v) Tween-20, pH 7.0 (SST buffer), followed by 500 ml of 0.12 M NaCl, 0.020M sodium chloride, pH 7.0 (SS buffer), the resin was blocked with 500 ml of 5% human serum albumin. The resin was washed with SS buffer and incubated with 500 ml of 3 mg/ml fibrinogen or plasma. The resin was washed twice with SS buffer, and the subjected to a mini-gel immuno-bead blot assay and Western Blot.
- The mini-gel immuno-bead blot assay was designed for quick analysis of several resins. A layer of 1% agarose (3.6 ml) was loaded in a 60 mm culture dish, over which was layered 0.8 ml of 1% low-melting agarose containing 100 ml of 1 mg pretreated resin. The bead-containing agarose gel was removed with a 50 ml Falcon tube and subjected to overnight transfer of proteins captured in the gel system onto a nitrocellulose membrane using 6.0 M guanidine (GuHCl). The transferred proteins were captured on the membrane and the immobilized fibrinogen was visualized with a primary anti-fibrinogen antibody, a secondary HRP-labeled antibody, and KPL chemiluminescent substrate.
- Approximately 40-90 mg of ToyoPearl 650-M amino resin displaying a library of D- or L-hexamers was loaded into a disposable BioRad column (BioRad). The resin beads were swollen overnight in 2 ml of 20% MeOH with rocking at 4° C. The column was drained, and the resin beads were washed with 20 column volumes (CV) of equilibration buffer (EQ buffer; 20 mM sodium citrate, 140 mM NaCl, pH 7.2-7.4). A sample of beads (0.05 ml) was blocked with 5 ml EQ buffer plus 3% human serum albumin at room temperature for 2 hours while rocking. The column was washed with 2 CV EQ buffer. Five milliliters of human plasma diluted 1× with EQ buffer was added to the resin beads. Binding of the peptide ligands to target protein was allowed to proceed for 30 minutes at room temperature while rotating. The plasma was drained from the column, and the resin beads were washed 10 times with 10 ml TBS+0.1% (v/v) Tween 20, followed by a final wash with 2×10 ml TBS.
- The transfer of specific target proteins from resin beads was accomplished as follows. A gel system was prepared with a 1% agarose base was overlayered with and a mixture of plasma-incubated resin beads (20 μl), green API control beads (3 μl) in 1.0 ml of 0.5% low melting (LMP) agarose. The proteins were transferred onto a PVDF membrane (Millipore) using 2.0 M NaCl, 20 mM sodium citrate buffer, pH 7.4, for 20 hours at room temperature. The membrane was then blocked with TBS plus 5% non-fat dry milk at room temperature for 2 hours while rocking. API was detected on the membrane with an HRP-labeled API primary antibody (ICN Cat. No 55236; Lot No. 01140) diluted 1:10,000 in TBS plus 5% nonfat dry milk for one hour at room temperature. The membrane was washed with TTBS buffer and the antibody detected with chemiluminescent substrate (ECL plus, Amersham) using Kodak BIOMAX MR film. After aligning the film with the agarose gel system, 70 beads corresponding to positive spots on the film were picked. The resin beads were stripped with 8 M guanidine followed by washing with TTBS buffer and TBS buffer. The resin beads were re-blocked and incubated with 200 ml diluted plasma according to the previous methods. Target protein was again transferred to a PVDF membrane, and API was detected according to the above methods. Five positive beads were picked, the peptide ligands of which were sequenced by Edman degradation on PROCISE Model 494 (Applied BioSystem) sequencer.
- The API-binding resin beads identified in the radiolabeled gel blots were washed with warm water to remove remaining agarose, and the resin beads were washed with 6.0 M guanidine as outlined above. After extensive washing with water and methanol, the resin beads were transferred to an Eppendorf tube, equilibrated with EQ buffer, and blocked for about 45 minutes with 1% casein in EQ buffer. After rinsing the resin beads with EQ buffer, the resin beads were exposed for 1 hour to 1.0 mg of purified API in EQ buffer. The API solution was removed and the resin beads were washed extensively with TBS plus 0.1% (v/v) Tween-20 buffer. For the transfer of API protein to a PVDF membrane, a gel was prepared with a 1% agarose base. The resin beads were then quantitatively transferred in 50 ml of EQ buffer to 1.0 ml of 0.5% low melting LMP agarose, containing 3 μl of PIKSIT™-API control beads (green agarose beads; Prometic, Cambridge, UK) in 0.010 M sodium phosphate, 0.05M NaCl, pH 7.6, buffer. The LMP agarose-resin mixture was quickly overlayered onto the 1% agarose gel bed as outlined above. Bound API was transferred from the resin beads onto PVDF membrane (Millipore) with 2.0 M NaCl, 20 mM sodium citrate buffer, pH 7.4, for 3 hours. Identification of positive resin beads was accomplished with HRP-labeled anti-API primary antibody as outlined above.
- API-binding peptide ligands from the 6-mer library include AKVSKG (SEQ ID NO: 45), HFVAPH (SEQ ID NO: 46), HFDLHR (SEQ ID NO: 47), and WWLHIN (SEQ ID NO: 33).
- Primary Screening of 6-mer Library for vWF/fVIII Ligands
- The ToyoPearl 650-M amino resin displaying the library of D- or L-hexamers (60-300 mm) was incubated either with plasma or purified vWF in TBS buffer or EQ buffer. The captured proteins were subsequently eluted stepwise from the resin beads with sodium chloride (0.5 M, 1.0 M, 2.0 M) and guanidine (2-6 M). The target proteins were detected immunologically after transfer onto a PVDF membrane. One of three detection strategies was employed to detect target protein binding. A one-step immunodetection assay using a specific HRP-conjugated polyclonal sheep anti-human vWF antibody was performed. A differential-subtractive immuno-detection assay entailed detecting proteins transferred onto membranes with specific HRP-conjugated polyclonal sheep anti-human vWF antibody in 1:10,000 dilution (AHP062P; Serotec) followed by exposure to chemiluminescence substrate ECLPlus. Membranes were stripped and re-probed with rabbit anti-human albumin antibody (No. A0433, Lot No. 031K4897 from Sigma) followed by secondary alkaline phosphatase-labeled goat anti rabbit antibody (Tropix). Following film development, films were aligned and dots that appeared on films for vWF and on albumin films were deemed background signal. Dots positive for vWF but not for albumin were considered positive. A detection assay using radio-labeled antibody also was performed. Freshly 1125-radiolabeled monoclonal anti-human vWF antibody, 101.104 (VWFAE; Enzyme Research) in dilution 1:250 in hSA-Hepes-0.14 M NaCl-Tween buffer was used for detection. After washing, membranes were exposed to Kodak films for 48 hrs at −80° C. Positive beads were picked and prepared for re-probing.
- All beads collected from several gels were pooled in the same tube, washed with water and incubated in 8 M Guanidine to remove remaining proteins before re-probing. After extensive washing with water and citrate buffer, the resin beads were blocked with 3% human albumin for 2 hours and incubated with human plasma. Resin beads were immobilized in agarose gels (6 cm×7 cm) and target protein was transferred to a PVDF membrane in 2 M NaCl for 20 hours. Membranes were blocked, incubated with 101.104 anti-vWF antibody, and detected with secondary goat/anti-mouse-HRP. In some experiments, sheep anti-human vWF antibody conjugated with HRP was used for detection. Positive beads were picked, washed, and the attached ligands were sequenced.
- vWF/fVIII binding peptides identified from the 6-mer library include QWFPEK (SEQ ID NO: 77), YHLGWL (SEQ ID NO: 76), YLHYQT (SEQ ID NO: 74), EDSWDV (SEQ ID NO: 67), LEDna2′EE (SEQ ID NO: 70), EADna2′ED (SEQ ID NO: 68), and YVDEDD (SEQ ID NO: 73).
- For some re-probing experiments, resin beads linked to target proteins were visualized by adding specific antibody and color substrate to facilitate further alignment. Detection of a target protein bound to the resin beads by non-labeled monoclonal antibody 101.104 anti-vWF was used followed by goat/anti-mouse antibody conjugated with alkaline phophatase and FastRed prior to immobilizing beads in the agarose gel. Additional substrate CDPStar was applied directly onto a gel with immobilized beads, and the gel was exposed to a Kodak film. Dark spots on the film were correlated with red spots on the gel to ensure appropriate alignment. The proteins from resin beads immobilized in the gel were transferred onto a membrane and developed again with radiolabeled monoclonal antibody against vWF. The films and gel were aligned, and resin beads that appeared positive in all stages were picked, washed, and attached ligands sequenced.
- This example illustrates the purification of fibrinogen from plasma using affinity chromatography employing a D-ARQFDF (SEQ ID NO: 20) resin.
- ToyoPearl AF-Amino 650 M resin beads displaying dried D-ARQFDF (SEQ ID NO: 20) peptide via an epsilon amino caproic acid (EACA) spacer were suspended in 20% methanol for a minimum of 2 hours before equilibration in 0.12-0.15 M NaCl, 0.020 M sodium citrate, pH 6.5-7.5. For 2.0-2.1 ml columns, about 0.5 mg of resin was obtained. The resin was subsequently packed in an Omni Column of 1.0-1.5 cm diameter and evaluated either on an ÄKTAExplorer System or BIO RAD BioLogic LP. Optical density at 280 nm-320 nm and conductivity was constantly monitored during the evaluations. Flow rates were selected according to column size to achieve linear velocities of 30-60 cm/hour and residence times between 5-8 minutes.
- All evaluations were performed at room temperature with cryo-rich plasma that had been 0.8 μm and 0.45 μm filtered. A linear velocity (LV) of 60 cm/H was maintained throughout the experiments. Fifty milliliters of plasma was applied at 1.5 ml/min (RT=6.7) onto 10 ml column (height 5.7 cm, CF=1.77 cm2) that had been equilibrated with 0.14 M NaCl, 0.020 M sodium citrate, pH 7.0 (EQ buffer). After the column was washed with EQ buffer to baseline, the fibrinogen was eluted with 0.3 M glycine, 0.5 M NaCl at pH 9.0 (10 CV). The column was regenerated with 2% Sarkosyl, 2.0 M guanidine-HCl, 30% ethanol, followed by a 70% ethanol/2% acetic acid mixture and stored in 20% methanol.
- Quantitative fibrinogen recoveries from plasma were consistently achieved at resin-to-plasma ratios of 1:3.5 to 1:4.5, giving a dynamic resin capacity of 6-8 g/L of resin at peptide ligand densities between 0.67-0.94 mmol/g resin. The D-ARQFDF (SEQ ID NO: 20) resin was used for over 15 runs with minimal changes in performance, dynamic resin capacity, or purity of fibrinogen eluates.
- The fibrinogen recoveries of two evaluations are provided in Table 3.
-
TABLE 3 Total Volume Fibrinogen* Fibrinogen Recovery (ml) (mg/ml) (mg) (%) Evaluation 1 Plasma Load 25 2.04 51 100 Flow thru + Post wash 40 <0.15 BD BD Elution 30 1.54 46 91 Evaluation 2 Plasma Load 25 2.04 51 100 Flow thru + Post wash 30 <0.15 BD BD Elution 15 3.6 54 100 *Fibrinogen antigen (nephelometric analysis) BD = below detection - As evidenced by the data of Table 3, recoveries of about 100% of the bound fibrinogen from the sample were achieved. This example demonstrates the purification of fibrinogen from plasma using an isolated or purified peptide of the invention.
- This example illustrates the purification of fibrinogen from plasma using a peptide consisting essentially of the amino acid sequence HWQ (SEQ ID NO: 7) attached to a chromatography resin.
- Five milliliters of plasma was applied at a flow rate of 0.2 ml/min. onto a 0.8 ml column (RT=4.0 min) containing a resin displaying the HWQ ligand, and was equilibrated with 0.14 M NaCl, 0.020M sodium citrate, pH 7.0 (EQ buffer). After washing the resin with EQ buffer and 0.5 M NaCl, pH 7.0, to baseline, the bound fibrinogen was eluted with 2.0 M NaCl, pH 7.0 or 0.3 M glycine, 0.5M NaCl, pH 9.0. All of the wash and elution buffers contained 0.020 M sodium citrate. Complete elution of fibrinogen was not achieved with either elution buffer. However, dynamic resin capacities of 5-8 mg were reached. The resin was regenerated with 2 M guanidine-HCl, 2% Sarkosyl, 30% ethanol and 70% ethanol/2% acetic acid, followed by storage in 20% methanol.
- This example demonstrates the purification of fibrinogen from plasma using an isolated or purified peptide ligand comprising three amino acids and attached to solid support.
- This example illustrates the purification of Apo-A1 lipoprotein from plasma using D-WFLHIN (SEQ ID NO: 58) peptide ligands.
- Apo-A1 lipoprotein purification was accomplished with D-WWLHIN (SEQ ID NO: 33) peptides and several analogs. Indeed, about 100% Apo-A1 lipoprotein depletion from plasma was repeatedly obtained with D-WWLHAN (SEQ ID NO: 56) and D-WWLHIN (SEQ ID NO: 58). Fourteen milliliters of fibrinogen-depleted plasma was loaded onto a 2.3 ml column (CF=0.785 cm2) at 0.4 ml/min. (LV=30 cm/H; RT=5.8) that had been equilibrated with 0.14 M NaCl, 0.020 M sodium citrate, pH 7.0 (EQ buffer). After the column was washed with EQ buffer to baseline, Apo-A1 lipoprotein was eluted with 2.0 M NaCl, 1% Tween-20, 0.020M sodium citrate, pH 7.0. The column was regenerated with 2.0 M guanidine-HCl, 2% Sarkosyl, and 2% acetic acid and stored in 20% methanol.
- This resin captured Apo-A1 lipoprotein at a resin to plasma ratio of 1:3.5 without any losses in the flow-through of albumin and API protein. SDS-PAGE data of reduced and non-reduced in-process samples demonstrated complete removal of Apo-A1 lipoprotein by WFLHIN (SEQ ID NO: 58) in flow-through of fibrinogen-depleted plasma. The recoveries of API, albumin, and Apo-A1 lipoprotein from F1 (fibrinogen)-depleted plasma using D-WFLHIN (SEQ ID NO: 58) are given in Table 4.
-
TABLE 4 Load Flow Through Elution Recovery (%) API (mg) 10.6 12.5 — 118 Apo-A1 (mg) 12.9 BD 9.1 71 Albumin (mg) 372 386 — 104 BD = below detection - According to the nephelometric analysis, 71% of Apo-A1 lipoprotein was recovered in 2.0 M NaCl, 1% Tween eluate, whereas 100% of API and albumin were recovered. Complete Apo-A1 lipoprotein depletion was accomplished with load of 14 ml of F1-depleted plasma on a 2.3 ml D-WFLHIN (SEQ ID NO: 58) displaying resin.
- This example illustrates the preparation of fibrinogen and Apo-A1 lipoprotein-depleted plasma using D-ARGFDF (SEQ ID NO: 20) and D-WWLHAN (SEQ ID NO: 56) peptide ligand resins. All column chromatographic steps were performed at room temperature using the ÄKTAExplorer or BioRad systems.
- Toyopearl AF Amino 650M resin displaying a peptide consisting essentially of the amino acid sequence D-ARQFDF (SEQ ID NO: 20) was suspended for 2 hours in 20% methanol. After washing with distilled water, the resin was packed into an Omni column (column volume (CV)=10 ml; diameter 1.5 cm; CF 1.77 cm2) and equilibrated in 0.14 M NaCl, 0.020 M sodium citrate, pH 7.0 (EQ buffer). Fifty milliliters of filtered plasma (0.80 mm, Nalgene Conn., Cat. No. 380-0080; 0.45 μm, Corning Calif., Cat. No. 431155; 0.20 μm, Nalgene PES, Cat. No. 165-0020) were loaded on the Omni columns at a linear velocity (LV) of 50 cm/H (flow rate (FR)=1.5 ml/min; residence time (RT)=6.7 minutes). The flow-through was collected in column volumes. After pooling fibrinogen-depleted plasma (50 ml), the flow-through was loaded onto a column comprising a resin displaying an Apo-A1 lipoprotein-binding ligand (D-WWLHIN (SEQ ID NO: 33)), as described below. The fibrinogen-binding column was washed with 12 CVs of EQ buffer and the fibrinogen eluted with 10 CVs of 0.3 M glycine, 0.5 M NaCl, pH 9.0. The column was regenerated with 10 CVs of 2% Sarkosyl, pH 8.0, followed by 10 CVs of 2.0 M guanidine (GuHCl). After washing with 5 CVs of distilled water, the column was further cleaned with 6 CVs of 30% ethanol and 6 CVs of 70% ethanol containing 2% acetic acid. The resin was stored in 20% methanol after rinsing extensively with distilled water.
- Toyopearl AF Amino 650M resin (2.5 g) displaying peptide ligands consisting essentially of an amino acid sequence D-WWLHAN (SEQ ID NO: 56), attached to the resin via an EACA spacer, was suspended in 20% methanol for 2 hours before packing into Omni columns and equilibration with EQ buffer (CV=10.6 ml, CF 1.77 cm2, CH=6.0 cm). Forty-two milliliters of the flow-through collected from the fibrinogen-binding column described above was loaded at a flow rate of 1.5 ml/min (LV 50 cm/H) and collected in CVs. The column was washed to baseline with 10 CVs of EQ buffer, and the Apo-A1 lipoprotein was eluted with 10 CVs of 2.0 M NaCl, 1% (v/v) Tween-20, pH 7.0. The column was regenerated in the same way as described for the D-ARQFDF (SEQ ID NO: 20)-bearing column. The flow-through pool herein will be named F1-Apo-depleted plasma and used for the evaluation of API-binding ligand resins.
- The regeneration steps described above, outlined for the D-ARQFDF-bearing column and the D-WWLHAN-bearing column, were implemented prior to first time use of the resins. Nephelometric protein determinations of fibrinogen, API, Apo-A1 lipoprotein, and albumin in process samples were performed with a DADE BEHRING Nephelometer BN II. A BioRAD GS-800 Calibrated Densitometer was used for densitometer analysis. Coagulation assays were performed with Automatic Coagulation Analyzer Electra 1400C. According to nephelometric and clotting analysis, fibrinogen was 100% captured by D-ARQFDF (SEQ ID NO: 20). API was recovered 100% in the flow-through of D-ARQFDF (SEQ ID NO: 20) resin, and 90-95% after D-WWLHAN (SEQ ID NO: 56) chromatography. Ninety percent of Apo-A1 lipoprotein was detected in the flow-through after treatment with the D-ARQFDF (SEQ ID NO: 20) resin, but no Apo-A1 lipoprotein could be detected by nephelometry and SDS-PAGE analysis after treating with the D-WWLHAN (SEQ ID NO: 56) resin.
- This example illustrates the purification of API using a L-HFVAPH (SEQ ID NO: 46) peptide ligand.
- Fibrinogen and Apo-A1 lipoprotein-depleted plasma (prepared in Example 5) was loaded at a linear velocity of 30 cm/hour (0.4 ml/min; RT=5.1) onto 2.0 ml column (CF=0.785 cm2) that had been equilibrated with 0.14 M NaCl, 0.020 M sodium citrate, pH 7.0 (EQ buffer). After the column was washed with EQ buffer and 2.0 M NaCl, 0.020 M sodium citrate, pH 6.0, to baseline, the API protein was eluted with 2.0 M NaCl, 1% Tween 20, 0.020 M sodium citrate, pH 6.0. The column was regenerated with 2.0 M guanidine-HCl, 2% Sarkosyl and 2% acetic acid and stored in 20% methanol. SDS-PAGE analysis of in-process samples (reduced and non-reduced samples) was performed using a Novex 8-16% gradient gel. Not all of the API was quantitatively eluted, but could be eluted using 2M guanidine. Purification of API protein to approximately 70% purity was accomplished with ligand HFVAPH (SEQ ID NO: 46) (isolated from an L-Library). Table 5 summarizes the nephelometric results of this run.
-
TABLE 5 Total Recovery Albumin Volume API API of bound Albumin Recovery (ml) (mg/ml) (mg) API (%) (mg/ml) (%) Load 9.5 0.74 7.03 22.6 100 Flow through 16 0.21 3.36 100 12.6 94 Postwash 8 <0.04 0.93 3.5 Elution Pool 8 0.15 1.2 33 <0.02 (with dialysis) Elution Pool 8 0.21 1.68 46 <0.02 (without dialysis) 2 M 4 0.1 0.4 11 <0.02 Guanidine#23 - As is apparent from the data set forth in Table 5, 46% of the captured API protein was recovered in the 2.0 MNaCl/1% Tween elution. As this ligand does not bind albumin from plasma in the presence of sodium citrate, 94% of the albumin was recovered in the flow-through. Thus, this example demonstrates the removal of API protein from plasma following the binding of API protein with a peptide ligand of the invention.
- Initial evaluation proved that a peptide having the amino acid sequence D-AKVSKG (SEQ ID NO: 45) or D-WWLHIN (SEQ ID NO: 33) binds albumin in addition to API protein in plasma. Conditions that prevented the binding of albumin from F1-Apo depleted plasma were identified. The capture of albumin by AKVSKG (SEQ ID NO: 45) and D-WWLHIN (SEQ ID NO: 33) can be prevented in the presence of 50 mM caproic acid or 1.0-2.2 M NaCl, respectively. An example for API purification with AKVSKG (SEQ ID NO: 45) is provided. F1-Apo-depleted plasma (10.7 ml) containing 50 mM caproic acid, was applied at 0.4 ml/min (LV=30 cm/h; RT=5.1) onto a 2.0 ml column (CF=0.785 cm2) that had been equilibrated with 0.14 M NaCl, 0.020 M sodium citrate, pH 7.0 (EQ buffer). After the column was washed with 19 CVs of EQ buffer to baseline, API protein was eluted with 2.0 M NaCl, 0.020 M sodium citrate, pH 6.0. The column was regenerated with 2.0 M guanidine-HCl, 2% Sarkosyl and 2% acetic acid and stored in 20% methanol.
- The process yields are given in Table 6.
-
TABLE 6 Total API Albumin API Volume API Recovery Albumin Recovery (mg/ml)+ (ml) (mg) (%) (mg/ml)* (%) Plasma 1.19 10.7 12.7 100 20 100 Flow through + 0.07 28.0 2.0 16 7.8 95 Post Wash Wash 0.11 12.0 1.3 10 0.63 3.6 (0.3 M NaCl) Wash 0.06 2.0 0.1 0.1 0.14 0.1 Wash <0.04 2.0 0.06 0.05 Elution 0.76 10.0 7.6 60 <0.02 (2 M NaCl) Elution 0.05 10.0 0.5 4 <0.02 (1% Tween) *Nephelometric Determination - As illustrated by the data in Table 6, 71% of the captured API protein was recovered in the 2.0 M NaCl elution pool according to the nephelometric analysis. The albumin concentration was below the detection limit in the API elution pool. The purity of the API eluate was 85% according to densitometric analysis. Thus, this example demonstrates the purification of API from plasma using a resin displaying a peptide ligand of the invention.
- This example illustrates the binding of paraoxonase by resin-bearing peptides comprising the amino acid sequence D-WWLHAN (SEQ ID NO:56).
- Paraoxonase binding to a WWLHAN (SEQ ID NO: 56)-displaying resin was evaluated according to the following protocol. Rabbit serum diluted 1/10 times with PBS (100 ml) was incubated in a rotating Eppendorf tube with 50 μl of D-WWLHAN (SEQ ID NO: 56)-displaying resin suspension containing approximately 5 μg of resin. The resin was previously soaked in 20% methanol overnight and washed 3 times with PBS to remove the methanol traces and resuspended in paraoxonase assay buffer (20 mM Tris pH 8.0, 150 mM NaCl, and 2 mM CaCl2). After 1 hour incubation at 37° C., resin beads were precipitated by centrifugation at 0.8000 g for 1 min in an Eppendorf microcentrifuge. Supernatants were transferred into separate Eppendorf tubes and resin bead pellets were resuspended in equal volumes of paraoxonase assay buffer. Paraoxonase activity of resin bead suspensions and supernatant solutions was measured. In particular, 100 μl of paraoxonase assay buffer containing 100 μm of DEPFMU (a fluorogenic substrate for paraoxonase detection) was mixed with 10 ml of supernatant or 10 μl of resin bead suspension, or the original serum solution in a standard microtiter plate well. After thorough mixing, the plate solution was incubated for 20 minutes at 37° C. Hydrolysis of DEPFMU was quantified by measuring the fluorescence level at 355 nm emission and at 460 nm excitation using a commercial fluorometer. The level of fluorescence correlates with the level of 6,8-difluoro-4-methylumbelliferyl released from DEPFMU as a result of paraoxonase-mediated hydrolysis. The actual amount of 6,8-difluoro-4-methylumbelliferyl released in the assay can be calibrated with a known amount of 6,8-difluoro-4-methylumbelliferyl.
- Following incubation with the resin, less than 4% of the original paraoxonase activity remained in the serum. Thus, this example demonstrates the ability of inventive peptide ligand to bind paraoxonase and remove paraoxonase from a sample, while leaving paraoxonase activity intact.
- This example illustrates the dissociation and recovery of paraoxonase from the peptide ligand-bearing resin of Example 8.
- Paraoxonase, or any plasma protein, can be recovered from the isolated or purified peptide of the invention coupled to a bead (i.e., a support) by several different approaches, including washing beads with buffers with high and low ionic strength, high and low pH, or buffers comprising up to 50% of ethylene glycol and different detergents. No paraoxonase activity was eluted from the beads into the supernatant without use of detergent. The maximal recovery of paraoxonase as measured by paraoxonase activity was about 32% of the original content and obtained using a buffer comprising 0.33% tergitol. Increases in tergitol concentration resulted in significant inhibition of paraoxonase activity. SDS PAGE analysis confirmed that the majority of the proteins were eluted using a tergitol concentration of 0.33%.
- Thus, this example illustrates the dissociation of a plasma protein, paraoxonase, from a peptide ligand-support complex, while retaining protein activity.
- This example demonstrates the binding of paraoxonase by multiple isolated or purified peptides of the invention.
- Several different D-WWLHIN (SEQ ID NO: 33) analogs were screened for the ability to bind to paraoxonase under the conditions described in Example 7. For this experiment, the following resins were tested: WWLHAN (SEQ ID NO: 56), AWLHIN (SEQ ID NO: 59), WALHIN (SEQ ID NO: 60), WWAHIN (SEQ ID NO: 61), WWLHIA (SEQ ID NO: 63), WYLHIN (SEQ ID NO: 35), WWLFIN (SEQ ID NO: 36), and na1′WLHIN (SEQ ID NO: 40).
- Following contact with resin-bound peptide ligands, little, if any, activity was detected in any of the remaining supernatants indicating that all of the resins bound paraoxonase efficiently. Significant activity was detected with bead fractions displaying D-WALHIN (SEQ ID NO: 60), D-WWAHIN (SEQ ID NO: 61), D-WWLFIN (SEQ ID NO: 36), and D-na1′WLHIN (SEQ ID NO: 40), indicating very efficient binding of paraoxonase. The maximal activity of paraoxonase was associated with the D-na1′WLHIN (SEQ ID NO: 40) resin.
- This example illustrates a method of removing vWF/fVIII from plasma using a peptide ligand of the invention, D-EADna2′ED (SEQ ID NO: 66), in chromatographic format.
- Pooled human plasma (20 ml) was added to 0.8 ml of resin and incubated for 30 minutes while gently rotating. Resin was settled under gravity or by short gentle centrifugation, and the supernatant was collected (the equivalent of “flow-through” of the previous examples). The resin was then packed into an Omni column and the chromatography was completed using the ÄKTAExplorer system. The flow rate was kept constant at 0.4 ml/min (LV=31 cm/h; retention time=2 minutes). After washing of the resin with EQ buffer to baseline, the bound proteins were eluted from the resin with 10 column volumes (CV) of 0.5 M NaCl, followed by 10 CVs of 0.75 M NaCl, 1.0 M NaCl/1% Tween (all in 0.02 M sodium citrate, pH 7.0) and 2.0 M guanidine. Twenty-five microliters of 0.4 M calcium chloride was added to each fraction collected, and the fractions were evaluated by OD reading and Western Blots for vWF and fVIII antigen. The fVIII activity of pooled fractions was determined by chromogenic and coagulation assays.
- The results of the recoveries of fVIII are summarized in Table 7.
-
TABLE 7 Total Total Volume FVIII FVIII Recovery * FVIII FVIII Recovery ** ID (ml) (IU/ml) * (IU) (%) (IU/ml) ** (IU) (%) Plasma 20 1.07 21.4 100 0.423 8.46 100 Load Flow- 20 0.08 1.6 7.5 0.08 1.6 18.9 Through Wash 10 0.12 1.2 5.6 0 0 0 (0.5 M NaCl) Elution 1 10 0.46 4.6 21.5 0.39 3.9 46 (0.75 M NaCl) Elution 2 10 0 0 0 0 0 0 (1.0 M NaCl) * Chromogenic Assay ** Coagulation Assay (Automatic Coagulation Analyzer Electra 1400C) - As is apparent from the data set forth in Table 7, fVIII activity dropped significantly in the flow-through compared to the starting material, which indicates the binding of fVIII to the resin. fVIII activity was recovered from the resin by elution with 0.75 M NaCl, and vWF was confirmed by Western Blot. Thus, this experiment demonstrates that D-EADna2′ED (SEQ ID NO: 66) resin binds vWF/fVIII and can remove the vWF/fVIII complex from plasma without disrupting activity of the target protein.
- All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein.
- The use of the terms “a” and “an” and “the” and similar referents in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. The terms “comprising,” “having,” “including,” and “containing” are to be construed as open-ended terms (i.e., meaning “including, but not limited to,”) unless otherwise noted. Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., “such as”) provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.
- Preferred embodiments of this invention are described herein, including the best mode known to the inventors for carrying out the invention. Variations of those preferred embodiments may become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventors expect skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.
Claims (67)
1. An isolated or purified peptide comprising no more than 10 amino acids and comprising an amino acid sequence Xaa1-Xaa2-Xaa3-Xaa4-Xaa5 (SEQ ID NO: 1), wherein
Xaa1 is a hydrophobic amino acid,
Xaa2 is a basic amino acid,
Xaa3 is a polar amino acid with a side chain comprising an amide,
Xaa4 is a hydrophobic amino acid or an aromatic amino acid, and
Xaa5 is an acidic amino acid,
and wherein the peptide binds to fibrinogen.
2. The isolated or purified peptide of claim 1 , wherein the amino acid sequence comprises an N-terminal amino acid that is a D-amino acid.
3. The isolated or purified peptide of claim 2 , wherein Xaa1 is Ala, Xaa2 is Arg, Xaa3 is Asn or Gln, and Xaa5 is Asp.
4. The isolated or purified peptide of claim 3 , wherein the peptide consists essentially of SEQ ID NO: 20 or SEQ ID NO: 21.
5. A composition comprising the peptide of claim 1 and a carrier.
6. An isolated or purified peptide comprising no more than 10 amino acids and comprising an amino acid sequence Gly-Xaa6-Arg-Xaa7 (SEQ ID NO: 2), wherein
Xaa6 is Pro or Gln, and
Xaa7 is any amino acid except Pro,
and wherein the peptide binds to fibrinogen.
7. The isolated or purified peptide of claim 6 , wherein Xaa6 is Pro.
8. The isolated or purified peptide of claim 6 , wherein the peptide consists essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs: 16, 22-27, and 29-32.
9. A composition comprising the peptide of claim 6 and a carrier.
10. An isolated or purified peptide comprising no more than 10 amino acids and comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 7-15, 17-19, and 28, wherein the peptide binds to fibrinogen.
11. The isolated or purified peptide of claim 10 , wherein the amino acid sequence is selected from the group consisting of SEQ ID NOs: 17-19 and comprises an N-terminal amino acid that is a D-amino acid.
12. A method of separating, isolating, purifying, characterizing, identifying, or quantifying fibrinogen in a sample, which method comprises (a) contacting a sample comprising fibrinogen with the peptide of claim 1 to form a fibrinogen-peptide complex, and (b) separating, isolating, purifying, characterizing, identifying, or quantifying the fibrinogen-peptide complex.
13. The method of claim 12 , wherein the peptide is attached to a support.
14. The method of claim 13 , wherein the support is a chromatography resin or a membrane.
15. The method of claim 12 , wherein the peptide consists essentially of an amino acid sequence of SEQ ID NO: 20 or SEQ ID NO: 21.
16. A method of separating, isolating, purifying, characterizing, identifying, or quantifying fibrinogen in a sample, which method comprises (a) contacting a sample comprising fibrinogen with the peptide of claim 6 to form a fibrinogen-peptide complex, and (b) separating, isolating, purifying, characterizing, identifying, or quantifying the fibrinogen-peptide complex.
17. The method of claim 16 , wherein the peptide is attached to a support.
18. The method of claim 17 , wherein the support is a chromatography resin or a membrane.
19. A method of separating, isolating, purifying, characterizing, identifying, or quantifying of removing fibrinogen in a sample, which method comprises (a) contacting a sample comprising fibrinogen with the peptide of claim 10 to form a fibrinogen-peptide complex, and (b) separating, isolating, purifying, characterizing, identifying, or quantifying the fibrinogen-peptide complex.
20. The method of claim 19 , wherein the peptide is attached to a support.
21. The method of claim 20 , wherein the support is a chromatography resin or a membrane.
22. An isolated or purified peptide comprising no more than 10 amino acids and comprising an amino acid sequence Xaa8-Xaa8-Xaa1-His-Xaa1-Xaa3 (SEQ ID NO: 3), wherein
Xaa1 is a hydrophobic amino acid,
Xaa3 is a polar amino acid with a side chain comprising an amide, and
Xaa8 is an aromatic amino acid, and
wherein the peptide binds to α1 proteinase inhibitor (API) and/or a protein complex comprising paraoxonase and Apo-A1 lipoprotein.
23. The isolated or purified peptide of claim 22 , wherein Xaa8 at position 1 is Trp, Tyr, 1-naphthylalanine (na1′), or 2-naphthylalanine (na2′), and Xaa3 at position 6 is Asn or Gln.
24. The isolated or purified peptide of claim 23 , wherein Xaa8 at position 2 is Trp, Tyr, na1′, or na2′, Xaa1 at position 3 is Leu, and Xaa1 at position 5 is Ile.
25. The isolated or purified peptide of claim 22 , wherein amino acid sequence comprises an N-terminal amino acid that is a D-amino acid.
26. A composition comprising the peptide of claim 22 and a carrier.
27. An isolated or purified peptide comprising no more than 10 amino acids and comprising an amino acid sequence His-Xaa8-Xaa9-Xaa1-Xaa10-Xaa2 (SEQ ID NO: 4), wherein
Xaa1 is a hydrophobic amino acid,
Xaa2 is a basic amino acid,
Xaa8 is an aromatic amino acid,
Xaa9 is an acidic amino acid or a hydrophobic amino acid, and
Xaa10 is a hydrophobic amino acid or His,
and wherein the peptide binds to API.
28. The isolated or purified peptide of claim 27 , wherein the peptide consists essentially of L-amino acids.
29. The isolated or purified peptide of claim 27 , wherein the peptide consists essentially of an amino acid sequence of SEQ ID NO: 46 or SEQ ID NO: 47.
30. A composition comprising the peptide of claim 27 and a carrier.
31. An isolated or purified peptide comprising no more than 10 amino acids and comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 36, 38, 39, 45, 48, 54, and 55, wherein the peptide binds to API.
32. The isolated or purified peptide of claim 31 , wherein the amino acid sequence comprises an N-terminal amino acid that is a D-amino acid.
33. A composition comprising the peptide of claim 31 and a carrier.
34. An isolated or purified peptide comprising no more than 10 amino acids and comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 59-62, wherein the peptide binds to a protein complex comprising Apo-A1 lipoprotein and paraoxonase.
35. A composition comprising the peptide of claim 34 and a carrier.
36. A method of separating, isolating, purifying, characterizing, identifying, or quantifying API and/or a protein complex comprising Apo-A1 lipoprotein and paraoxonase in a sample, which method comprises (a) contacting a sample comprising API and/or a protein complex comprising Apo-A1 lipoprotein and paraoxonase with the peptide of claim 22 to form an API-peptide complex or a complex comprising the peptide and Apo-A1 lipoprotein and/or paraoxonase, and (b) separating, isolating, purifying, characterizing, identifying, or quantifying the API-peptide complex and/or the complex comprising the peptide and Apo-A1 lipoprotein and/or paraoxonase.
37. The method of claim 36 , wherein the peptide is attached to a support.
38. The method of claim 37 , wherein the support is a chromatography resin or a membrane.
39. The method of claim 36 , wherein the peptide consists essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs: 34, 39, 40, 50, 54 and 55.
40. A method of separating, isolating, purifying, characterizing, identifying, or quantifying API in a sample, which method comprises (a) contacting a sample comprising API with the peptide of claim 27 to form an API-peptide complex, and (b) separating, isolating, purifying, characterizing, identifying, or quantifying the API-peptide complex.
41. The method of claim 40 , wherein the peptide is attached to a support.
42. The method of claim 41 , wherein the support is a chromatography resin or a membrane.
43. A method of separating, isolating, purifying, characterizing, identifying, or quantifying API in a sample, which method comprises (a) contacting a sample comprising API with the peptide of claim 31 to form an API-peptide complex, and (b) separating, isolating, purifying, characterizing, identifying, or quantifying the API-pep tide complex.
44. The method of claim 43 , wherein the peptide is attached to a support.
45. The method of claim 44 , wherein the support is a chromatography resin or a membrane.
46. A method of separating, isolating, purifying, characterizing, identifying, or quantifying a protein complex comprising Apo-A1 lipoprotein and paraoxonase in a sample, which method comprises (a) contacting a sample comprising a protein complex comprising Apo-A1 lipoprotein and paraoxonase with the peptide of claim 34 to form a complex comprising Apo-A1 lipoprotein, paraoxonase, and the peptide of claim 34 , and (b) separating, isolating, purifying, characterizing, identifying, or quantifying the complex.
47. The method of claim 46 , wherein the peptide is attached to a support.
48. The method of claim 47 , wherein the support is a chromatography resin or a membrane.
49. An isolated or purified peptide comprising no more than 6 amino acids and comprising an amino acid sequence Xaa4-Xaa5-Xaa5, wherein
Xaa4 is a hydrophobic amino acid or an aromatic amino acid, and
Xaa5 is an acidic amino acid, and
wherein the peptide does not comprise His, Arg, or Lys, and binds to von Willebrand Factor (vWF).
50. The isolated or purified peptide of claim 49 , wherein Xaa5 is Asp or Glu.
51. The isolated or purified peptide of claim 49 , wherein the peptide consists essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs: 64, 65, 68-73 and 111.
52. A composition comprising the peptide of claim 49 and a carrier.
53. An isolated or purified peptide comprising no more than 10 amino acids and comprising an amino acid sequence Tyr-Leu-Xaa1-Xaa4-Xaa12-Thr, wherein
Xaa4 is a hydrophobic amino acid or an aromatic amino acid,
Xaa1 is an aromatic amino acid or His, and
Xaa12 is a hydrophobic amino acid or a polar amino acid, and
wherein the peptide binds to vWF.
54. The isolated or purified peptide of claim 53 , wherein the Xaa1 is His or Tyr, Xaa4 is Tyr or Ala, and Xaa12 is Gln or Leu.
55. An isolated or purified peptide comprising no more than 10 amino acids and comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 67, 76, and 77, wherein the peptide binds to vWF.
56. A method of separating, isolating, purifying, characterizing, identifying, or quantifying vWF in a sample, which method comprises (a) contacting a sample comprising vWF with the peptide of claim 49 to form a vWF-peptide complex, and (b) separating, isolating, purifying, characterizing, identifying, or quantifying the vWF-peptide complex.
57. The method of claim 56 , wherein the peptide is attached to a support.
58. The method of claim 57 , wherein the support is a chromatography resin or a membrane.
59. The method of claim 57 , wherein Factor VIII is bound to vWF, and the Factor VIII is co-purified with the vWF.
60. A method of separating, isolating, purifying, characterizing, identifying, or quantifying vWF in a sample, which method comprises (a) contacting a sample comprising vWF with the peptide of claim 53 to form a vWF-peptide complex, and (b) separating, isolating, purifying, characterizing, identifying, or quantifying the vWF-peptide complex.
61. The method of claim 60 , wherein the peptide is attached to a support.
62. The method of claim 61 , wherein the support is a chromatography resin or a membrane.
63. The method of claim 61 , wherein Factor VIII is bound to vWF, and the Factor VIII is co-purified with the vWF.
64. A method of separating, isolating, purifying, characterizing, identifying, or quantifying vWF in a sample, which method comprises (a) contacting a sample comprising vWF with the peptide of claim 55 to form a vWF-peptide complex, and (b) separating, isolating, purifying, characterizing, identifying, or quantifying the vWF-peptide complex.
65. The method of claim 64 , wherein the peptide is attached to a support.
66. The method of claim 65 , wherein the support is a chromatography resin or a membrane.
67. The method of claim 64 , wherein Factor VIII is bound to vWF, and the Factor VIII is co-purified with the vWF.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/802,730 US20090258834A1 (en) | 2002-04-15 | 2007-05-24 | Plasma protein-binding ligands |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37209102P | 2002-04-15 | 2002-04-15 | |
US10/414,524 US7223734B2 (en) | 2002-04-15 | 2003-04-14 | Plasma protein-binding ligands |
US11/802,730 US20090258834A1 (en) | 2002-04-15 | 2007-05-24 | Plasma protein-binding ligands |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/414,524 Continuation US7223734B2 (en) | 2002-04-15 | 2003-04-14 | Plasma protein-binding ligands |
Publications (1)
Publication Number | Publication Date |
---|---|
US20090258834A1 true US20090258834A1 (en) | 2009-10-15 |
Family
ID=29250792
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/414,524 Expired - Fee Related US7223734B2 (en) | 2002-04-15 | 2003-04-14 | Plasma protein-binding ligands |
US10/414,523 Expired - Fee Related US7217507B2 (en) | 2002-04-15 | 2003-04-14 | Method for detecting ligands and targets in a mixture |
US11/797,318 Abandoned US20080160501A1 (en) | 2002-04-15 | 2007-05-02 | Plasma protein-binding ligands |
US11/802,730 Abandoned US20090258834A1 (en) | 2002-04-15 | 2007-05-24 | Plasma protein-binding ligands |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/414,524 Expired - Fee Related US7223734B2 (en) | 2002-04-15 | 2003-04-14 | Plasma protein-binding ligands |
US10/414,523 Expired - Fee Related US7217507B2 (en) | 2002-04-15 | 2003-04-14 | Method for detecting ligands and targets in a mixture |
US11/797,318 Abandoned US20080160501A1 (en) | 2002-04-15 | 2007-05-02 | Plasma protein-binding ligands |
Country Status (8)
Country | Link |
---|---|
US (4) | US7223734B2 (en) |
EP (2) | EP1494695A4 (en) |
JP (1) | JP4585766B2 (en) |
CN (1) | CN100525829C (en) |
AU (2) | AU2003231731A1 (en) |
CA (2) | CA2482856A1 (en) |
HK (1) | HK1082040A1 (en) |
WO (2) | WO2003088990A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015073418A2 (en) * | 2013-11-15 | 2015-05-21 | President And Fellows Of Harvard College | Methods and assays for factor viii activity |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1138692A1 (en) | 2000-03-29 | 2001-10-04 | Erasmus Universiteit Rotterdam | Fragments of human chorionic gonadotropin (hcg) as immunoregulator |
US7358330B2 (en) | 2001-03-29 | 2008-04-15 | Biotempt B.V. | Immunoregulatory compositions |
US20050037430A1 (en) * | 2000-03-29 | 2005-02-17 | Biotempt B.V. | Methods and uses for protein breakdown products |
USRE43279E1 (en) | 2000-03-29 | 2012-03-27 | Biotemp B.V. | Compositions capable of reducing elevated blood urea concentration |
US7365173B2 (en) * | 2002-02-04 | 2008-04-29 | American National Red Cross | Method for the production of pure virally inactivated butyrylcholinesterase |
US20070015230A1 (en) * | 2002-04-15 | 2007-01-18 | Hammond David J | Identification and characterization of analytes from whole blood |
US20060275753A1 (en) * | 2002-04-15 | 2006-12-07 | Hammond David J | Recovery of analytes using combinatorial libraries |
WO2003088990A1 (en) * | 2002-04-15 | 2003-10-30 | American National Red Cross | Plasma protein-binding ligands |
US20060275829A1 (en) * | 2002-04-15 | 2006-12-07 | Hammond David J | Combinatorial library for proteomic investigations |
US20030232379A1 (en) * | 2002-06-14 | 2003-12-18 | Amorese Douglas A. | Methods of performing array based assays and compositions for practicing the same |
EP1521841B1 (en) * | 2002-07-11 | 2010-04-14 | The American National Red Cross | Method for identifying individual active entities from complex mixtures |
US8216854B2 (en) * | 2003-01-07 | 2012-07-10 | Biotex, Inc. | Device and method for measuring analytes |
US7510848B2 (en) * | 2003-04-04 | 2009-03-31 | North Carolina State University | Prion protein binding materials and methods of use |
CA2522483A1 (en) * | 2003-04-14 | 2004-10-28 | Julia T. Lathrop | Method for identifying ligands specific for structural isoforms of proteins |
US7374900B2 (en) | 2003-04-17 | 2008-05-20 | The American National Red Cross | Fluorescent substrates for detecting organophosphatase enzyme activity |
US20050277205A1 (en) * | 2004-02-20 | 2005-12-15 | Ki-Bum Lee | Multicomponent magnetic nanorods for biomolecular separations |
US7422696B2 (en) * | 2004-02-20 | 2008-09-09 | Northwestern University | Multicomponent nanorods |
EP1580559B1 (en) * | 2004-03-23 | 2013-12-25 | Bio-Rad Laboratories, Inc. | Methods for reducing the variance between analyte concentrations taken from complex sample mixtures |
WO2005123952A2 (en) | 2004-06-09 | 2005-12-29 | Pathogen Removal And Diagnostic Technologies Inc. | Particles embedded ina porous substrate for removing target analyte from a sample |
GB0414825D0 (en) * | 2004-07-02 | 2004-08-04 | Biostatus Ltd | Gel formulations and uses thereof |
BRPI0519399A2 (en) * | 2004-12-23 | 2009-01-20 | Novo Nordisk As | solid carrier material and method for isolating antibodies or derivatives thereof |
CA2602913C (en) * | 2005-03-23 | 2016-01-05 | Bio-Rad Laboratories, Inc. | Method for purifying proteins |
JP2008538112A (en) * | 2005-03-23 | 2008-10-09 | バイオ−ラッド ラボラトリーズ インコーポレーティッド | Diverse chemical libraries bound to small particles with paramagnetic properties |
US20090247421A1 (en) * | 2005-03-23 | 2009-10-01 | Egisto Boschetti | Diverse chemical libraries bound to small particles with paramagnetic properties |
EP1734367A1 (en) * | 2005-06-14 | 2006-12-20 | Cellzome Ag | Process for the identification of novel enzyme interacting compounds |
US8263342B2 (en) * | 2005-10-27 | 2012-09-11 | Yale University | Urinary proteomic biomarker patterns in preeclampsia |
ES2662042T3 (en) * | 2006-01-06 | 2018-04-05 | Emd Millipore Corporation | Chromatographic matrices of affinity and methods of manufacture and use thereof |
US20070287991A1 (en) * | 2006-06-08 | 2007-12-13 | Mckay William F | Devices and methods for detection of markers of axial pain with or without radiculopathy |
GB0623607D0 (en) * | 2006-11-27 | 2007-01-03 | Haemostatix Ltd | Tissue adhesive |
WO2012134416A2 (en) * | 2009-11-18 | 2012-10-04 | Arizona Board Of Regents Acting For And On Behalf Of Arizona State University | Peptide ligands |
GB201201751D0 (en) | 2012-02-01 | 2012-03-14 | Haemostatix Ltd | Haemostatic wound dressing |
EP3514543B1 (en) * | 2013-11-07 | 2021-05-05 | Boston Cell Standards LLC | Quantitative controls and calibrators for cellular analytes |
AU2015258962B2 (en) * | 2014-05-15 | 2020-07-02 | Cleveland Heartlab, Inc. | Compositions and methods for purification and detection of HDL and ApoA1 |
CN109975467B (en) * | 2017-12-28 | 2023-05-02 | 贵州中烟工业有限责任公司 | Method for measuring epoxypropanol in main stream smoke of cigarette |
CN114088860B (en) * | 2021-10-27 | 2024-08-23 | 上海市食品药品检验研究院 | Method and system for separating enterotoxin C in milk by multidimensional liquid chromatography |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5010175A (en) * | 1988-05-02 | 1991-04-23 | The Regents Of The University Of California | General method for producing and selecting peptides with specific properties |
US5011686A (en) * | 1987-09-21 | 1991-04-30 | Creative Biomolecules, Inc. | Thrombus specific conjugates |
US5133866A (en) * | 1988-03-24 | 1992-07-28 | Terrapin Technologies, Inc. | Method to identify analyte-bending ligands |
US5235039A (en) * | 1991-06-10 | 1993-08-10 | Eli Lilly And Company | Substrates for hiv protease |
US5498538A (en) * | 1990-02-15 | 1996-03-12 | The University Of North Carolina At Chapel Hill | Totally synthetic affinity reagents |
US5723579A (en) * | 1996-02-02 | 1998-03-03 | Bayer Corporation | Fibrinogen binding peptides |
US5780090A (en) * | 1995-07-26 | 1998-07-14 | Firmenich Sa | Flavored products and a process for their preparation |
US5965709A (en) * | 1991-08-14 | 1999-10-12 | Genentech, Inc. | IgE antagonists |
US5994309A (en) * | 1997-07-25 | 1999-11-30 | Angstrom Pharmaceuticals, Inc. | Anti-invasive and anti-angiogenic compositions and methods |
US6004757A (en) * | 1994-01-07 | 1999-12-21 | Beth Israel Hospital | Substrate specificity of a protein kinases |
US6207397B1 (en) * | 1996-04-18 | 2001-03-27 | Ariad Pharmaceuticals, Inc. | In vitro fluorescence polarization assay |
US7217507B2 (en) * | 2002-04-15 | 2007-05-15 | The American National Red Cross | Method for detecting ligands and targets in a mixture |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06100604B2 (en) * | 1985-06-06 | 1994-12-12 | 和光純薬工業株式会社 | Fraction detection reagent kit for α-fetoprotein and fraction detection method |
JPH0724768B2 (en) * | 1985-11-07 | 1995-03-22 | 味の素株式会社 | Afinophoa based on polyamino acid |
US5650489A (en) | 1990-07-02 | 1997-07-22 | The Arizona Board Of Regents | Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof |
US5639603A (en) * | 1991-09-18 | 1997-06-17 | Affymax Technologies N.V. | Synthesizing and screening molecular diversity |
US5236039A (en) * | 1992-06-17 | 1993-08-17 | General Electric Company | Balanced-line RF electrode system for use in RF ground heating to recover oil from oil shale |
WO1994002515A1 (en) | 1992-07-21 | 1994-02-03 | Bunsen Rush Laboratories Inc. | Oligomer library formats and methods relating thereto |
US5840485A (en) * | 1993-05-27 | 1998-11-24 | Selectide Corporation | Topologically segregated, encoded solid phase libraries |
AU686186B2 (en) * | 1993-05-27 | 1998-02-05 | Aventisub Ii Inc. | Topologically segregated, encoded solid phase libraries |
EP0679658A4 (en) | 1993-06-25 | 1997-06-04 | Kyowa Hakko Kogyo Kk | Endothelin-antagonizing peptide. |
US5688997A (en) * | 1994-05-06 | 1997-11-18 | Pharmacopeia, Inc. | Process for preparing intermediates for a combinatorial dihydrobenzopyran library |
US5856083A (en) | 1994-05-06 | 1999-01-05 | Pharmacopeia, Inc. | Lawn assay for compounds that affect enzyme activity or bind to target molecules |
US5834318A (en) * | 1995-05-10 | 1998-11-10 | Bayer Corporation | Screening of combinatorial peptide libraries for selection of peptide ligand useful in affinity purification of target proteins |
SE9502286D0 (en) | 1995-06-22 | 1995-06-22 | Pharmacia Ab | Process for detection, quantification and / or identification of a peptide |
US5981254A (en) * | 1997-10-30 | 1999-11-09 | Haemacure Corporation | Process for producing thrombin from plasma |
NZ505424A (en) * | 1998-01-23 | 2002-09-27 | Csl Ltd | Purification of fibrinogen |
IL128193A (en) | 1999-01-22 | 2008-03-20 | Yeda Res & Dev | Rhamnosyl-transferase gene and uses thereof |
CA2864069A1 (en) * | 1999-10-29 | 2001-05-03 | Novartis Vaccines And Diagnostics S.R.L. | Neisserial antigenic peptides |
JP2004500350A (en) * | 1999-12-02 | 2004-01-08 | ブイ アイ テクノロジーズ インコーポレイテッド | Methods for identifying ligands for target molecules |
US20030232054A1 (en) * | 2000-01-25 | 2003-12-18 | Tang Y. Tom | Novel nucleic acids and polypeptides |
DE60121923T2 (en) * | 2000-03-16 | 2006-11-30 | Biacore Ab | METHOD FOR DETECTING ANALYZES ELIGIBLE FROM SURFACE-LINKED LIGANDS |
EP2213743A1 (en) * | 2000-04-12 | 2010-08-04 | Human Genome Sciences, Inc. | Albumin fusion proteins |
CA2413978C (en) * | 2000-06-21 | 2008-12-16 | Bioarray Solutions, Ltd. | Multianalyte molecular analysis |
US6783969B1 (en) * | 2001-03-05 | 2004-08-31 | Nuvelo, Inc. | Cathepsin V-like polypeptides |
US7022486B2 (en) * | 2001-08-13 | 2006-04-04 | Douglas A. Campbell | Peptide sequence tags and method of using same |
WO2003083436A2 (en) * | 2002-03-26 | 2003-10-09 | Dyax Corp. | Fibrinogen binding moieties |
US7374900B2 (en) * | 2003-04-17 | 2008-05-20 | The American National Red Cross | Fluorescent substrates for detecting organophosphatase enzyme activity |
-
2003
- 2003-04-14 WO PCT/US2003/011798 patent/WO2003088990A1/en not_active Application Discontinuation
- 2003-04-14 US US10/414,524 patent/US7223734B2/en not_active Expired - Fee Related
- 2003-04-14 AU AU2003231731A patent/AU2003231731A1/en not_active Abandoned
- 2003-04-14 EP EP03721710A patent/EP1494695A4/en not_active Withdrawn
- 2003-04-14 JP JP2003586604A patent/JP4585766B2/en not_active Expired - Fee Related
- 2003-04-14 US US10/414,523 patent/US7217507B2/en not_active Expired - Fee Related
- 2003-04-14 CA CA002482856A patent/CA2482856A1/en not_active Abandoned
- 2003-04-14 WO PCT/US2003/011799 patent/WO2003089922A1/en active Application Filing
- 2003-04-14 AU AU2003225008A patent/AU2003225008A1/en not_active Abandoned
- 2003-04-14 CN CNB038137275A patent/CN100525829C/en not_active Expired - Fee Related
- 2003-04-14 EP EP03747009A patent/EP1495318A4/en not_active Withdrawn
- 2003-04-14 CA CA002482529A patent/CA2482529A1/en not_active Abandoned
-
2006
- 2006-02-23 HK HK06102446.0A patent/HK1082040A1/en not_active IP Right Cessation
-
2007
- 2007-05-02 US US11/797,318 patent/US20080160501A1/en not_active Abandoned
- 2007-05-24 US US11/802,730 patent/US20090258834A1/en not_active Abandoned
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5011686A (en) * | 1987-09-21 | 1991-04-30 | Creative Biomolecules, Inc. | Thrombus specific conjugates |
US5133866A (en) * | 1988-03-24 | 1992-07-28 | Terrapin Technologies, Inc. | Method to identify analyte-bending ligands |
US5010175A (en) * | 1988-05-02 | 1991-04-23 | The Regents Of The University Of California | General method for producing and selecting peptides with specific properties |
US5498538A (en) * | 1990-02-15 | 1996-03-12 | The University Of North Carolina At Chapel Hill | Totally synthetic affinity reagents |
US5235039A (en) * | 1991-06-10 | 1993-08-10 | Eli Lilly And Company | Substrates for hiv protease |
US5965709A (en) * | 1991-08-14 | 1999-10-12 | Genentech, Inc. | IgE antagonists |
US6004757A (en) * | 1994-01-07 | 1999-12-21 | Beth Israel Hospital | Substrate specificity of a protein kinases |
US5780090A (en) * | 1995-07-26 | 1998-07-14 | Firmenich Sa | Flavored products and a process for their preparation |
US5723579A (en) * | 1996-02-02 | 1998-03-03 | Bayer Corporation | Fibrinogen binding peptides |
US6207397B1 (en) * | 1996-04-18 | 2001-03-27 | Ariad Pharmaceuticals, Inc. | In vitro fluorescence polarization assay |
US5994309A (en) * | 1997-07-25 | 1999-11-30 | Angstrom Pharmaceuticals, Inc. | Anti-invasive and anti-angiogenic compositions and methods |
US6696416B1 (en) * | 1997-07-25 | 2004-02-24 | Angstrom Pharmaceuticals, Inc. | Anti-invasive and anti-angiogenic compositions |
US7217507B2 (en) * | 2002-04-15 | 2007-05-15 | The American National Red Cross | Method for detecting ligands and targets in a mixture |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015073418A2 (en) * | 2013-11-15 | 2015-05-21 | President And Fellows Of Harvard College | Methods and assays for factor viii activity |
WO2015073418A3 (en) * | 2013-11-15 | 2015-07-09 | President And Fellows Of Harvard College | Methods and assays for factor viii activity |
EP3069141A4 (en) * | 2013-11-15 | 2017-05-10 | President and Fellows of Harvard College | Methods and assays for factor viii activity |
US10114017B2 (en) | 2013-11-15 | 2018-10-30 | President And Fellows Of Harvard College | Methods and assays for factor VIII activity |
US11067572B2 (en) | 2013-11-15 | 2021-07-20 | President And Fellows Of Harvard College | Methods and assays for factor VIII activity |
Also Published As
Publication number | Publication date |
---|---|
WO2003088990A1 (en) | 2003-10-30 |
US7223734B2 (en) | 2007-05-29 |
AU2003225008A1 (en) | 2003-11-03 |
EP1495318A4 (en) | 2008-05-21 |
CN100525829C (en) | 2009-08-12 |
US20030212253A1 (en) | 2003-11-13 |
CN1659432A (en) | 2005-08-24 |
CA2482856A1 (en) | 2003-10-30 |
US20080160501A1 (en) | 2008-07-03 |
EP1495318A1 (en) | 2005-01-12 |
AU2003231731A1 (en) | 2003-11-03 |
US7217507B2 (en) | 2007-05-15 |
HK1082040A1 (en) | 2006-05-26 |
WO2003089922A1 (en) | 2003-10-30 |
US20030211471A1 (en) | 2003-11-13 |
WO2003089922A8 (en) | 2004-05-06 |
JP4585766B2 (en) | 2010-11-24 |
JP2005522712A (en) | 2005-07-28 |
CA2482529A1 (en) | 2003-10-30 |
EP1494695A1 (en) | 2005-01-12 |
EP1494695A4 (en) | 2006-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7223734B2 (en) | Plasma protein-binding ligands | |
JP4229704B2 (en) | Fc region polypeptide binding molecule | |
JP6567577B2 (en) | TFPI inhibitors and methods of use | |
AU2002254683A1 (en) | Binding molecules for Fc-region polypeptides | |
US7879792B2 (en) | Synthetic peptide inhibitors of thrombin and thrombin activation of protease activated receptors 1 and 4 | |
US5994310A (en) | Peptide ligands for affinity purification of human Factor VIII | |
AU706019B2 (en) | Peptide ligands which bind to von Willebrand factor | |
JP4500494B2 (en) | Antigenic epitope of factor VIII, inhibitors directed against the epitope and their use | |
JP2002323488A (en) | Blood coagulation accelerator and container for blood test | |
JPH0665298A (en) | Polypeptide and antiplatelet antibody adsorbent | |
JPH0680693A (en) | Polypeptide and antiplatelet antibody adsorbent using the same | |
JPH0625287A (en) | Polypeptide and antiplatelet antibody adsorbent using the same | |
JPH0630989A (en) | Polypeptide and antiplatelet antibody adsorbing material using the same | |
JPH0654906A (en) | Polypeptide and antiplatelet antibody adsorbent using polypeptide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |